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INTRODUCTION
The yeast Candida albicans is a common commensal organ-
ism in humans and animals, and it is a major opportunistic
fungal pathogen (244). Mucocutaneous infections—commonly
known as thrush—are the usual manifestation of the disease,
and although not normally life-threatening, they represent a
problem of considerable socioeconomic importance. Oral can-
didiasis is frequently seen in dental practice (163) and in pa-
tients with human immunodeficiency virus infection or AIDS
(185), and Candida vaginitis is one of the more common ail-
ments treated by general practitioners (113).
Severe, intractable mucocutaneous infections are less com-
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mon and fall into two broad categories, chronic mucocutane-
ous candidiasis and chronic vaginal candidiasis. These are dis-
cussed separately below. Systemic infections occur in patients
whose bodily defenses have been compromised by cancer, by
major surgery, or by treatment with cytotoxic or immunosup-
pressive drugs. Indeed, the increasing sophistication of medical
technology has unfortunately been associated with an upsurge
in Candida infection in the hospital environment (258), to the
extent that it now causes 7% of all nosocomial infections (347)
and is directly responsible for morbidity and mortality substan-
tially in excess of that attributable to the patients’ underlying
conditions (355).
Oral and vaginal thrush can be triggered by a variety of
changes in physiological and immunological homeostasis (62,
313). Chronic mucocutaneous candidiasis and other severe
mucocutaneous infections are usually associated with defects
or weaknesses in the cell-mediated immune response (182),
whereas hematogenous and disseminated infections are more
common in patients with dysfunctional neutrophils (181) or
neutropenia (57, 195). These observations suggest that both
phagocytic cells and specific cell-mediated immune responses
participate in the host response against the organism; but de-
spite the fact that many different modes of Candida killing
have been demonstrated in in vitro systems, those that function
in vivo have not yet been convincingly defined.
Evidence is accumulating that T cells contribute to the host
response, in both mucocutaneous and experimental systemic
infections, by providing cytokine-mediated activation signals to
mononuclear and polymorphonuclear phagocytes (Table 1). In
developing a synthesis of these data, however, two crucial
themes must be borne in mind. The first is whether fundamen-
tally different mechanisms are responsible for recovery from
mucosal as distinct from systemic infections, and the second
relates to the specific changes or abnormalities in the host
response that predispose to recurrent infection.
Overview
The mechanisms of Candida killing and their regulation by
cytokines have been subject to detailed analysis in vitro with
both human and mouse phagocytic cells. However, in vivo,
there is a crucial difference between animal models of candi-
diasis and the human disease in that most humans are colo-
nized with C. albicans shortly after birth and, in adult life,
infections occur in the presence of both humoral and cell-
mediated immune responses to antigens of the yeast. Hence, a
true ‘‘primary’’ infection in humans occurs only in the early
neonate, and it is necessary to exercise some caution in apply-
ing the results of studies in humans to an understanding of the
underlying mechanisms of host resistance.
It is difficult to make direct comparisons between human and
animal studies, and our knowledge has not yet advanced to
the point where it is possible to draw general conclusions. For
this reason, results from the two experimental systems are
considered separately. The different manifestations of human
infections with C. albicans are described, and this is followed
by an outline of cellular responses to the yeast. The utility of
animal models is then addressed, with particular emphasis on
strain variation and the influence of genetic factors on patho-
genesis and the evolution of the immune response. With this
background, models of mucosal and systemic infection are
discussed, and we conclude by considering immunoregulatory
interactions in Candida infection and their role in the estab-
lishment of chronic disease.
HUMAN STUDIES
Chronic Mucocutaneous Candidiasis
Chronic mucocutaneous candidiasis is an all-encompassing
term for a collection of syndromes characterized by recurrent
infection of the mucous membranes, skin, and nails by C.
albicans. Although the disease is frequently seen in association
with endocrinopathies, it is generally recognized that the main
predisposing factor is a defect in the cell-mediated immune
response (183, 184). Patients with chronic mucocutaneous can-
didiasis show a number of different patterns of abnormalities in
immunological responsiveness (Table 2), but it is important to
note that there is no Candida-specific defect common to all
groups. Nevertheless, therapy directed at restoration of cellu-
lar immune function generally results in remission, and this
link between systemic cell-mediated immunity and mucosal
defense mechanisms has been crucial in developing an under-
standing of the pathogenesis of the disease.
Chronic Vaginal Candidiasis
It is estimated that three out of four women will experience
at least one episode of vaginal candidiasis during their repro-
ductive years (161), and the prevalence of Candida carriage in
the vagina ranges from 20% in New Zealand (5) to 40% in
TABLE 1. Summary of the cytokines relevant to C. albicans infection and their major functions
Cytokine Major functionsa
IL-1.............................Mediates acute-phase response; acts with other cytokines to activate T- and B cells; induces hematopoietic growth factors
IL-2.............................Induces clonal expansion of and cytokine synthesis by antigen-specific T cells
IL-3.............................Stimulates proliferation and differentiation of hematopoietic stem cells
IL-4.............................Modulates T- and B-cell differentiation, growth, and function; induces NK and LAK cell activity; enhances macrophage
antigen processing and presentation
IL-6.............................Induces acute-phase proteins; stimulates T-cell differentiation, growth, and effector function
IL-8.............................Mediates neutrophil chemotaxis; exerts other proinflammatory effects
IL-10...........................Inhibits cytokine secretion by T cells and monocytes; stimulates B-cell proliferation and differentiation
IL-12...........................Stimulates growth and IFN-g production by T cells; enhances NK and LAK activity
IFN-g..........................Activates macrophages, PMNL, and NK cells; increases MHC class II antigen expression; inhibits virus growth and cell
proliferation
TNF-a ........................Affects growth and differentiation of T cells; induces adhesion molecules; activates endothelial cells
TGF-b ........................Suppresses T- and B-lymphocyte functions; stimulates inflammatory cells
G-CSF ........................Stimulates proliferation and differentiation of neutrophils; enhances activity and survival of the mature cells
GM-CSF ....................Induces growth and differentiation of granulocyte/macrophage progenitor cells; enhances the function of the mature cells
M-CSF (CSF-1).........Stimulates the growth of precursor cells and enhances the function of mature macrophages
a The function and regulation of these cytokines have been discussed in detail in recent reviews (6, 188).
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Nigeria (118). Although some women never contract vulvovag-
inal candidiasis and others experience infrequent episodes, a
third subpopulation, possibly comprising as many as 5% of all
adult women (314), suffer from recurring infections that result
in morbidity and physical and emotional distress. Numerous
environmental and lifestyle factors (pregnancy, oral contracep-
tives, antibiotics, diabetes mellitus, tight clothing, etc.) have
been identified as risk factors for Candida vaginitis, but the
majority of women with recurrent vulvovaginal candidiasis do
not have recognizable predisposing factors (313).
Immune defects in chronic vaginitis. Recurrent vaginal can-
didiasis occurs in ostensibly immunocompetent women who
are not unusually susceptible to other infections, in the pres-
ence of established humoral and cell-mediated immune re-
sponses against the yeast. A comparison of antibody profiles
from women with chronic recurrences and appropriate con-
trols has not revealed any consistent differences in either se-
rum (162) or vaginal secretions (142), although one study iden-
tified a unique band pattern in cervicovaginal secretions from
culture-positive patients with a classical clinical presentation
(306). Nevertheless, it seems probable that susceptibility in
these women is associated with some form of T-lymphocyte
defect.
One of the major difficulties in approaching a systematic
analysis of immune deficiencies in Candida vaginitis is the
variability in severity of symptoms of the disease (160). As is
the case in chronic mucocutaneous candidiasis, chronic vaginal
candidiasis may be the outward expression of a number of
different immunological defects. For example, Candida vagini-
tis is associated with both allergic hypo- and hyperreactivity
(219), as well as with polymorphisms in the third component of
complement (18). Superimposed on these factors are (i) vari-
ations in T-lymphocyte physiology during the menstrual cycle
(264), (ii) changes in nonspecific (209) and specific (174) im-
mune responses related to fluctuations in the levels of proges-
terone or estradiol, (iii) the effects of genetically determined or
progesterone-mediated alterations in monocyte accessory cell
function (175), and (iv) the influence of sex steroids, such as
progesterone, on the yeast-mycelium transition and the candi-
dacidal activity of neutrophils (239).
Nonetheless, studies of acquired immunity in women with
chronic Candida vaginitis have found evidence of deficiencies
in cell-mediated immune responsiveness (326). The prolifera-
tive response to stimulation with Candida antigens of lympho-
cytes from patients with vaginal candidiasis was found to be
specifically reduced in comparison with controls (361), and the
response of the control lymphocytes could be blocked by co-
culture with either serum or lymphocytes from the patients.
Candida-specific antibody decreased lymphocyte proliferation
by inhibiting the uptake and/or processing of Candida antigens
by macrophages and the recognition by lymphocytes of Can-
dida antigen on the macrophage surface (358). When the effect
of macrophages on Candida-specific lymphoproliferation was
assessed directly in cell-mixing experiments (359), the response
of lymphocytes from the patients was restored to the normal
range if they were incubated in the presence of control mac-
rophages. Conversely, macrophages from the patients inhib-
ited the responses of control lymphocytes. Inhibition could be
reversed by the addition to the cultures of ibuprofen or indo-
methacin, showing that the effect was due to the secretion by
macrophages of prostaglandin E2, which blocked lymphocyte
proliferation.
Different patterns of cell-mediated immune responses have
been reported in other studies. One series of patients with
recurrent vaginal candidiasis showed low T-lymphocyte counts
twice as frequently as controls (223), and in this group, in vitro
proliferation to Candida antigens bore no relation to the
course of the disease. A more comprehensive longitudinal
study demonstrated a transient loss of Candida-specific de-
layed cutaneous skin test reactivity during episodes of symp-
tomatic vaginitis (124), but Candida-specific lymphocyte pro-
liferation and lymphokine production were similar to those in
controls during both acute episodes of vaginitis and periods of
remission.
In some patients with Candida vaginitis, antifungal treat-
ment does not invariably alleviate symptoms. Candida-specific
immunoglobulin E (IgE) antibodies as well as prostaglandin E2
were identified in vaginal fluid from a high proportion of sub-
jects in this category (360), suggesting that a vaginal allergic
response might induce prostaglandin E2 synthesis, thus sup-
pressing cell-mediated immune responses and predisposing to
recurrent infection. In a subsequent clinical trial (272), there
was a significant reduction in the frequency of recurrences
after desensitization in a group of patients unresponsive to all
other forms of therapy.
Given the number and complexity of the factors that can
influence clinical presentation, it is hardly surprising that there
is little agreement among the various studies of immune func-
tion in these patients. It is important to recognize that even in
carefully matched patients with culture-proven infections, an-
tigen processing and host responses may vary. This is exempli-
fied by the detection of antibodies to enolase, a protein that
acts as an immunodominant antigen in both humans (131, 349)
and mice (325), in only a proportion of a cohort of patients
with Candida vaginitis, grouped according to the presence or
absence of active infection (247).
Many different mucosal models have been studied in at-
tempts to identify the responses that might be deficient or
abnormal in these women, with little success; and it is clear that
progress in this area will depend on a more complete under-
standing of the complex immunological relationships between
the yeast and the host.
CELLULAR RESPONSES TO CANDIDA INFECTION
Lymphocyte Proliferative Responses
In most cases of chronic mucocutaneous candidiasis and
chronic vaginal candidiasis, Candida-specific lymphoprolifera-
tion is impaired. Considerable effort has been directed towards
an analysis of this response, in terms of the requirements for
stimulation, cytokine production by the responding lympho-
cytes, and, more recently, identification of the protein recog-
nized by the T cells.
TABLE 2. Patterns of abnormalities of cellular immunity in
patients with chronic mucocutaneous candidiasisa
Group DTH(Candida)
No. of
T cells
Lymphocyte
transformation MIF production
Candida Mitogen Candida Mitogen
1 Anergy Few SN SN SN SN
2 Anergy N SN N SN N
3 Anergy N N N SN N
4 Negative N SN N SN N
5 Negative N N N SN N
6 Negative N SN N N ?
7 Negative N N N N N
a Reproduced with permission from Kirkpatrick (184). Abbreviations: MIF,
migration inhibitory factor; SN, subnormal or absent; N, normal response; ?,
value unknown.
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Human lymphocytes show strong proliferative responses af-
ter stimulation in vitro with antigens of C. albicans, and this is
dependent upon a degree of genetic compatibility between
antigen-presenting cells and the responding lymphocytes. Ac-
tivation of T lymphocytes by Candida allergen was found to
require the presence of human leukocyte antigen (HLA)-
Dw1.DR1- or Dw12.DR2-compatible macrophages (241), and
the magnitude of the proliferative response showed a good
correlation with the HLA type of the responding cells (240). In
particular, a significant association was found between low
responses and HLA-B15, whereas high responses correlated
with HLA-B7 as well as Dw1.
Lymphoproliferation could be induced by culture either with
glutaraldehyde-inactivated C. albicans blastospores or with a
phosphorylated glucomannan-protein complex of the cell wall
(32), although a low-protein mannan extract was much less
active. After 7 to 10 days of incubation, the cultured cells
displayed some but not all natural killer (NK) cell markers,
expressed cytotoxicity against both NK-susceptible and NK-
resistant tumor cell lines, and produced both interleukin-2
(IL-2) and gamma interferon (IFN-g) (31). A monoclonal an-
tibody against the class II determinant of the HLA complex
inhibited proliferation irrespective of the Candida antigen used
(32), again indicating that presentation took place through
major histocompatibility complex (MHC) class II molecules.
Stimulation of human peripheral blood mononuclear cells
(PBMC) with C. albicans or its antigens also results in the
production of a number of different cytokines. PBMC from
healthy female donors produced both tumor necrosis factor
(TNF) and IL-1 in proportion to the concentration of viable
organisms used for challenge (167), although the levels of IL-1
and TNF produced by any individual appeared to be indepen-
dently regulated. Differences in the time course of cytokine
production were also observed (151), in that IFN-g was pro-
duced on day 1 after stimulation, whereas synthesis of TNF-a
occurred more slowly. Analysis of the expression of cytokine
genes in cultures of human PBMC stimulated either with Can-
dida antigen (139) or with mannoprotein constituents of C.
albicans (33) revealed early and long-lasting production of
mRNAs for IL-1b, TNF-a, and IL-6, as well as appreciable
levels of mRNAs for IL-2, granulocyte-macrophage colony-
stimulating factor (GM-CSF), and IFN-g. When cytokine pro-
tein synthesis was inhibited by cycloheximide, a superinduction
of mRNAs for IL-4, IL-10, and, more markedly, IFN-g was
observed (33). Mannoprotein was unable to stimulate consis-
tent expression of the genes encoding IL-4, IL-5, or IL-10.
Separation of the crude, carbohydrate-rich extract of the C.
albicans cell wall into two major proteoglycan constituents
revealed that immunogenic activity was associated with a high-
molecular-mass, polydisperse material (333). This fraction was
as efficient as the crude extract in inducing lymphocyte prolif-
eration, production of IL-2 and IFN-g, and generation of cy-
totoxicity against NK-sensitive target cells. The active constit-
uent was not mitogenic but acted through interaction with the
T-cell receptor complex. Chromatographic separation identi-
fied a 65-kDa mannoprotein that stimulated proliferation and
production of IL-1b, IFN-g, and IL-6 but not IL-4 from human
PBMC as the immunodominant antigen for cell-mediated im-
mune responses in normal humans (332). When administered
to mice, this preparation elicited strong delayed-type hyper-
sensitivity (DTH) but relatively poor protective responses
(222).
In addition to the stimulatory activities that have already
been defined, members of a family of mannose oligosacchar-
ides derived from a cetyltrimethylammonium bromide prepa-
ration of C. albicans cell wall were potent inhibitors of lym-
phoproliferation stimulated by Candida and other antigens
(259). The properties and biological functions of mannan have
been the subject of excellent reviews (109, 236), and the reg-
ulation of Candida-specific immune responses will be further
considered below.
Candidacidal Activity of Phagocytic Cells
Polymorphonuclear leukocytes (PMNL) represent the first
line of defense in the control of Candida infections. Optimal
phagocytosis by human PMNL requires fresh human serum
(254), the opsonic activity of which depends primarily on com-
plement activated via both the alternative and classical path-
ways (316). Human serum deficient in either the second (224)
or the fifth (295) component of complement was able to effi-
ciently opsonize Saccharomyces cerevisiae or C. albicans for
ingestion by human neutrophils, but in the absence of C3,
phagocytosed yeasts were not killed (363). Activation of C3
also generates chemotactic factors (265) that act to recruit
leukocytes to the site of infection.
In vitro, PMNL readily ingest large numbers of Candida
yeasts (254), and a constant percentage of organisms are killed
within the cell regardless of the number ingested. The remain-
der germinate (270) and grow out through the cell membrane.
The relatively low efficiency of killing within human neutro-
phils may be associated with functional differences in the two
classes of phagosomes (72), as incompletely sealed vacuoles
support antimicrobial processes substantially less well than
completely sealed ones. The yeast, too, may differ in suscepti-
bility to intracellular killing. More blastospores of strains that
were virulent for mice survived intracellularly in human and
mouse PMNL than did those of attenuated strains (270). Fur-
thermore, progeny from blastospores of the attenuated strain
that had germinated within the PMNL regained virulence for
mice and behaved similarly to the virulent strains in tests with
human and mouse phagocytes in vitro.
In contrast, hyphal elements may be more susceptible to
attack by PMNL (81). For example, human neutrophils are
highly efficient in clearing germinating Candida cells from en-
dothelial cell monolayers (115). Killing is mediated by activa-
tion of the respiratory burst and focal release of toxic oxygen
species, but the generation of oxidants may not always be
sufficient to mediate hyphal killing in the absence of comple-
mentary, nonoxidative mechanisms (319). In addition to direct
killing of the yeasts or hyphae, death of PMNL in a lesion may
also act to control the infection, as dying PMNL release a
substance that has a strong candidastatic effect (218). This was
identified as an abundant calcium-binding protein with gener-
alized antimicrobial activity, originally described in neutrophils
as the L1 myelomonocytic antigen or the cystic fibrosis antigen
(315), and now termed calprotectin (320).
Nonspecific activation of PMNL by treatment with lipopoly-
saccharide, for example, strongly enhanced growth inhibition
of C. albicans by increasing the number of yeasts ingested per
neutrophil as well as the number of neutrophils phagocytosing
fungal cells (248). Activation resulted in the production of
IL-1, IL-6, and TNF-a, but the antifungal activity was shown to
be mediated by the release of the iron-binding protein lactof-
errin. Furthermore, a mannoprotein component of C. albicans
was shown to be as efficient as lipopolysaccharide, GM-CSF,
and IL-8 in potentiating lactoferrin-mediated inhibition of
Candida growth in vitro (249).
Activation may also be mediated via specific receptors on
the cell surface. Human PMNL constitutively express detect-
able levels of the b-chain but not the a-chain of the IL-2
receptor and respond functionally to IL-2 by enhanced lacto-
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ferrin-mediated antifungal activity (104). Oxidative metabo-
lism, as measured by superoxide anion production, was not
involved in this response. IL-2 binds to C. albicans (334) and,
when complexed in this manner, increases the lymphoprolif-
erative response of normal human peripheral blood lympho-
cytes to the yeast. The significance of this phenomenon in vivo
has yet to be established, but it is not unreasonable to suggest
that it may increase the efficiency of presentation of this cyto-
kine to the PMNL.
Human cells of the monocyte/macrophage lineage also rep-
resent an important component of the host defense system
against Candida infection. Peripheral blood monocytes are
able to damage hyphal and pseudohyphal elements of C. albi-
cans without completely ingesting them (97). The dominant
mechanism of killing involves the myeloperoxidase-dependent
pathway, although monocytes from patients with myeloperox-
idase deficiency were also able to damage hyphae. The killing
of C. albicans blastospores by human monocytes (299) and
human alveolar macrophages (317) has also been attributed to
oxidative mechanisms. In contrast, peritoneal macrophages
were able to kill very few ingested Candida organisms (256), so
the ‘‘innate’’ effector activity of these cells may depend on the
source from which they were derived.
The yeast, however, may be able to defend itself actively
against the effector activity of monocytes/macrophages. After 1
h of incubation with C. albicans blastoconidia, a proportion of
human peripheral blood monocytes that had phagocytosed the
yeast had died, as indicated by staining with ethidium bromide,
even though the cell membranes showed no sign of penetration
by the fungi (93). The mechanism by which the monocytes are
killed remains to be clarified, and the relevance of this subtle
interaction to the process of colonization and invasion in vivo
is not yet clear.
Although freshly isolated monocytes and macrophages clear-
ly express intrinsic anti-Candida activity, numerous studies
have demonstrated that expression of the full candidacidal
function of both PMNL and monocytes/macrophages requires
activation either by colony-stimulating factors (CSFs) or by
T-lymphocyte-derived cytokines (Table 3).
Effect of Cytokines on Human Phagocytes
Polymorphonuclear leukocytes. Cytokines can be elaborated
not only by antigen-specific T lymphocytes but also by NK cells
and by the phagocytic cells themselves. In humans, NK activity
is mediated by a population of large granular lymphocytes.
These cells are unable to kill Candida organisms directly (367)
but, when activated with antigens in vitro, release TNF-a
(103), GM-CSF (48), and an as yet uncharacterized PMNL-
activating factor (101), all of which stimulate neutrophil-me-
diated inhibition of fungal growth (101, 102, 121, 269). Other
cytokines, such as the monocyte-derived neutrophil chemotac-
tic factor IL-8, have also been found to augment PMNL func-
tion in vitro. IL-8 stimulated antifungal activity in PMNL but
not in monocytes (105); in contrast to IFN-g and TNF-a, it did
not stimulate the production of superoxide in the cells, sug-
gesting that the fungal killing might take place via oxygen-
independent pathways.
After exposure to the yeast, PMNL themselves have been
shown to produce TNF-a (106), so that activation can take
place in an exponential autocrine loop. TNF is chemotactic for
PMNL and monocytes (226), so autocrine production of this
cytokine may also act to increase the recruitment of inflam-
matory cells to the site of infection. PMNL can be activated to
produce TNF-a not only by C. albicans and GM-CSF but also
by IL-2, via binding to the b-chain of the IL-2 receptor ex-
pressed on the cell surface (352). Treatment of the neutrophils
with cycloheximide did not affect induction of TNF-a mRNA
by IL-2 but blocked induction by GM-CSF. In contrast, TNF-a
mRNA was superinduced in cycloheximide-treated neutrophils
activated by exposure to C. albicans. Thus, it is evident that
transcription of the TNF-a genes is responsive to different
cytokines and activating factors and that these are indepen-
dently regulated. It has been further suggested (100) that the
complexity of the neutrophil response to cytokines indicates
that they may be active participants in the afferent phase of the
immune response rather than simply being end-stage effector
cells.
IFN-g acts both separately from (323) and synergistically
with (102) TNF-a to augment the candidacidal activity of hu-
man PMNL in vitro, although another study (98) demonstrated
that the two cytokines have markedly different effects on neu-
trophil function. In the last study (98), priming of neutrophils
with either IFN-g or TNF-a increased early superoxide gen-
eration; but IFN-g augmented hyphal killing, whereas TNF-a
reduced neutrophil fungicidal activity to nearly 40% less than
that of unprimed control cells, even though it enhanced super-
oxide responses more dramatically than IFN-g. Furthermore,
IFN-g added during priming failed to correct TNF-a-associ-
ated functional defects in neutrophil anti-Candida responses.
Thus, cytokine-induced augmentation of the respiratory burst
may not necessarily reflect enhancement of the candidacidal
activity of the cells.
This conclusion has been reinforced by studies on the effect
of granulocyte colony-stimulating factor (G-CSF) on the oxi-
dative burst and microbicidal activity of neutrophils. These
experiments showed that G-CSF enhanced superoxide produc-
tion in response to both opsonized blastoconidia and pseudo-
hyphae (279) and significantly increased bacterial phagocytosis
and bactericidal activity. Although treatment of normal human
PMNL with recombinant G-CSF in vitro increases Candida
killing (362), the activated neutrophils have been shown to
exert fungicidal activity against pseudohyphal elements of the
yeast (278) but not against blastoconidia (280). Two other
cytokines, IL-1 and GM-CSF, have also been reported to en-
hance phagocytosis by human neutrophils (119).
Macrophages. Human monocytes respond to C. albicans by
increasing production of complement factors (155) and GM-
CSF (154), and these functions, as well as the expression of
complement receptor 3 (CD11b/CD18), are regulated by trans-
forming growth factor beta (TGF-b) (156). Monocytes also
produce both TNF-a and IL-6 after stimulation in vitro with
heat-killed clinical isolates or agerminative mutants of C. albi-
cans (262, 263). TNF-a could be induced, in a dose-dependent
fashion, by stimulation of human monocytes with a phospho-
TABLE 3. Effect of cytokines on killing of C. albicans by
human phagocytes
Cytokine Cell type Effect on Candida killing Reference(s)
IL-1 PMNL Increased 119
IL-3 Monocytes Increased 120, 312, 350
IL-8 PMNL Increased 105
IFN-g Macrophages Increased 204, 206, 235
PMNL Increased 98, 323
TNF-a PMNL Increased 101, 102, 121, 269
PMNL Decreased 98
G-CSF PMNL Increased 362
GM-CSF PMNL Increased 119
Monocytes Increased 120, 312, 350
M-CSF Monocytes Increased 350
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lipomannan antigen of the yeast (171), although the yield was
significantly increased by prestimulation of the cells with
IFN-g. These responses by the monocytes themselves may be
an important mechanism both for opsonization of the fungus
and for the initiation of a local inflammatory reaction.
Opsonized Candida species are ingested by both monocytes
and monocyte-derived macrophages, but unopsonized Candida
organisms are phagocytosed only by the latter, primarily via
binding to the mannose receptor (204, 205). IFN-g, typically
produced by activated T lymphocytes, is one of the major
factors that augment the phagocytic and candidacidal activities
of human macrophages (235), and treatment with IFN-g in-
creases the capacity of monocytes and monocyte-derived mac-
rophages to ingest and kill both opsonized (206) and unopso-
nized (204) Candida yeasts. Monocyte-derived macrophages
from cord blood were much less responsive than those from
adults (205), a significant finding in view of the increased
susceptibility of neonates to infection. Killing was associated
with a Candida-stimulated respiratory burst and release of
myeloperoxidase-dependent oxidants and beta-glucuronidase
in monocytes but not in monocyte-derived macrophages, which
lack myeloperoxidase (203). Therefore, although monocytes
and macrophages function similarly in their interaction with C.
albicans, they appear to use different oxygen reactive products
for intracellular killing (330). Surprisingly, the increased can-
didacidal activity of IFN-g-activated macrophages was associ-
ated with reduced expression of the macrophage mannose
receptor, suggesting that this might reflect enhanced coupling
of this receptor to microbicidal functions (206).
Human alveolar macrophages also present an efficient bar-
rier to infection with C. albicans (346), and treatment in vitro
with IFN-g, IL-1a, or lipopolysaccharide but not IL-2 signifi-
cantly augments Candida killing. The candidacidal but not the
phagocytic activity of alveolar macrophages declined progres-
sively in culture, although this effect was reversible by exposure
to IFN-g, IL-1a, or lipopolysaccharide. Treatment of alveolar
macrophages with a calcium ionophore showed that the phago-
cytic and killing events were ion dependent (343) and that the
enhancement of intracellular candidacidal activity correlated
with an augmented anti-Candida activity of cation-activated
proteases.
Incubation of human monocytes with recombinant human
GM-CSF or IL-3 enhanced both production of superoxide
anion and cytotoxic activity for C. albicans (120, 312, 350).
Macrophage CSF (M-CSF) also augmented Candida killing,
but to a lesser extent (350). Under different experimental con-
ditions, monocytes cultured in medium supplemented with au-
tologous serum and a combination of recombinant human
IFN-g and IL-3 formed multinucleated giant cells that pro-
duced twice as much superoxide anion per unit of cytoplasmic
protein as controls (117) and killed substantially more of the
ingested yeasts. A more detailed examination of monocyte
candidacidal activity in vitro (350) found that monocytes aged
in medium lost their spontaneous candidacidal activity. The
cultured monocytes did not reacquire activity after addition of
IFN-g, and supplementation of the medium with IFN-g failed
to maintain this function. In contrast, monocytes maintained in
GM-CSF or IL-3 exhibited a high level of candidacidal activity
throughout the period of culture, and these cytokines were also
able to restore the response of cells aged in culture. Thus,
GM-CSF and IL-3 may potentiate the anti-Candida activity of
human monocytes via a different pathway than IFN-g.
In addition, monocyte function can be regulated by interac-
tions with lymphokine-activated killer (LAK) cells, which are
derived from large granular lymphocytes by culture with IL-2.
Electron microscopy has shown that LAK cells make intimate
contact with the yeast, particularly the fungal germ tubes (7),
but do not themselves display any consistent candidacidal or
candidastatic activity. Exposure of cultured monocytes to LAK
cells substantially suppressed their ability to control fungal
growth (354), and prior activation of the monocytes with GM-
CSF or IL-3 rendered them even more susceptible to the
inhibitory effect. Processing and presentation of C. albicans
antigens, as well as expression of mRNA for IL-1a and IL-1b
in response to antigenic stimulation, were also downregulated
in monocytes cultured with GM-CSF or IL-3 after exposure to
LAK cells (353). Although IFN-g was unable to sustain the
candidacidal function of cultured monocytes (350), it protected
them from inhibition by the LAK cells (353, 354).
These human experiments have revealed that the candi-
dacidal function of human phagocytes can be modulated in a
variety of ways by treatment with different cytokines in vitro
and provided evidence that the effector functions are subject to
regulation by other lymphoid cells. However, the relevance of
the different effector pathways to the various manifestations of
the human disease remains obscure, and the efficiency of cy-
tokine therapy in modulating the course and outcome of in-
fection has still to be firmly established. For example, local
administration of recombinant human G-CSF to neutropenic
AIDS patients resulted in a transient increase in neutrophil
counts that was associated with a significant enhancement of
their fungicidal activity (345); but even though infusion of
M-CSF increased monocyte migration and phagocytosis of C.
albicans (180), clinical trials of M-CSF therapy for fungal in-
fections in bone marrow transplant recipients have not yet
provided definitive evidence for a beneficial effect (237).
MURINE MODELS OF CANDIDIASIS
The crucial factors involved in recovery from and resistance
to the human disease are almost impossible to identify because
of the genetic heterogeneity of the population and the diverse
and often unpredictable effects of other confounding factors,
such as lifestyle and concomitant infections. The only way in
which these variables can be eliminated or identified and their
effects evaluated is by the use of animal models. It is not the
intention here to review the many different animal models of
Candida infection, which have been discussed in detail else-
where (4); instead, the main focus will be on recent immuno-
logical studies in the mouse.
Characteristics of the Infection
Systemic candidiasis in inbred mice closely resembles the
human disease. Both brain and kidney involvement are com-
mon in disseminated Candida infections in humans (244, 252),
and in mice also, these organs are a prime focus for infection
(199, 251). As the kidney possesses a phagocytic system which
is able to eliminate the organisms as efficiently as those of the
liver and spleen (36), its unusual susceptibility in mice is some-
what surprising but may be related to the extremely aggressive
challenges used in many of the experimental systems. When
the number of Candida organisms used to establish infection is
reduced, the most obvious tissue damage occurs in the brain
(251).
An unusual feature of these lesions is that the brains, in
CBA/CaHmice in particular, often exhibit large accumulations
of growing yeasts in the absence of any detectable inflamma-
tory response (251). Abscesses, consisting of mixed inflamma-
tory cells together with yeast and hyphal forms of the organism,
form gradually, and the infection eventually resolves. With
increasing doses, mice of all strains begin to die; however, in
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our experience, deaths typically occur within the first 5 to 7
days (23), after which time survivors suffer no untoward effects
except for a behavioral abnormality associated with chronic
osteomyelitis in the vicinity of the inner ear (25). The proximal
cause of death has not been unequivocally established, but as
the kidneys of moribund mice that are killed for ethical reasons
are distended with Candida organisms and appear grossly and
microscopically abnormal, a likely reason for this early mor-
tality is kidney failure caused by acute fungal pyelonephritis.
Infection in Inbred Strains
Insight into the basic mechanisms of host defense can best
be obtained by comparing inflammatory and immune re-
sponses in inbred strains of mice that exhibit different patterns
of susceptibility to infection with the yeast (Table 4). Suscep-
tibility to systemic candidiasis has been evaluated by gross
measures, such as mortality; by colony counts in infected tis-
sues; and by histological evaluation of the severity of lesions in
the tissues.
Mortality is a good correlate of susceptibility and resistance
in viral and bacterial infections; however, in Candida infec-
tions, other factors appear to supervene. Opsonization by com-
plement is critical in reducing the initial fungal burden, and
when inbred strains are ranked by mortality or colony counts in
the kidney, those deficient in the fifth component of comple-
ment die after challenge with substantially lower doses of C.
albicans than complement-sufficient mice (16, 149). However,
in complement-sufficient strains, there is no correlation be-
tween mortality or colonization patterns and other known ge-
netic markers, such as those within the mouse MHC (207, 208).
Histopathological assessment has shown two distinct pat-
terns of tissue destruction in the brains of inbred mice of
different strains (21). These can be classified as severe, or type
1, lesions, characterized by numerous large abscesses contain-
ing yeast and mycelial growth forms within the necrotic debris
together with an inflammatory infiltrate consisting of mononu-
clear and PMNL, and mild, or type II, lesions, which show
similar characteristics but are small and infrequent. Mild and
severe tissue damage can also be discerned in other organs, but
to a lesser extent. However, the type I and type II patterns of
tissue destruction do not correlate with either mortality or the
number of viable organisms in the brain (16). Although the
latter was generally greater in type 1 (CBA/CaH and AKR)
than in type II (BALB/c and DBA/1) mice, the kinetics of
fungal growth and clearance in the two types of mice were
similar (15, 17), peaking on day 4 after infection and falling
away rapidly thereafter. The propensity to develop mild or
severe tissue damage is heritable, and studies in F1 and F2
hybrid mice have shown that this is controlled by a single
codominant gene (or gene complex) that segregates in Men-
delian fashion (27). The variables that determine the expres-
sion of type I or type II lesions have not yet been defined but
may be related to either a qualitative or quantitative difference
in the effector functions of bone marrow-derived phagocytic
cells or a difference in the development or evolution of cell-
mediated immune responses.
The expression of protective responses after infection also
correlates with the patterns of tissue damage in type I and type
II mice. When mice are infected with a sublethal dose of C.
albicans, allowed to recover, and rechallenged, brain lesions in
CBA/CaH (type I) mice are much smaller and less numerous
than those in controls, whereas in BALB/c (type II) mice, the
protective effect is less apparent (22). Protection can be pas-
sively transferred by serum from immune mice (28), suggesting
that it is mediated by a Candida-specific antibody. Infection
with C. albicans results in the production of a wide spectrum of
antibodies, and studies in outbred mice have demonstrated
protection mediated by an autoantibody against a 90-kDa heat
shock protein (214). However, both the immunodominant
epitopes recognized and the major antibody isotypes produced
differ in type I and type II mice (Table 4).
Role of complement. As noted above, mice genetically defi-
cient in the fifth component of complement are extremely
susceptible to lethal challenge with C. albicans (149, 228), but
its influence in determining patterns of resistance to infection
in inbred strains has only recently been elucidated (17).
The candidacidal activity of phagocytic cells from normal
and C5-deficient mice is equivalent (229), indicating that the
opsonizing and/or chemotactic properties of C5 are important
factors in the process of containment and elimination of the
yeast. An intact complement system contributes to the early
inhibition of the growth of C. albicans in normal and immune
congenic resistant B10.D2 mice (200), but the presence or
absence of C5 does not affect the development of specific
immune responses or the ultimate outcome of challenge. Sim-
ilar results were obtained in studies of experimental cutaneous
candidiasis in C5-deficient mice (357), in that complement-
deficient animals took longer to clear the infections, but the
epidermal neutrophilic infiltrate in the skin of these animals
was equivalent to that in the normal animals. When the phys-
ical barrier presented by the stratum corneum is penetrated,
complement mediates an acute neutrophilic pustular response
that restricts Candida proliferation and prevents further inva-
sion of the tissue (266).
C5-deficient inbred mice show higher levels of tissue colo-
nization than C5-sufficient strains (16), and a comparison of
brain abscesses in DBA/1 (C51) and DBA/2 (C50) mice showed
a relative paucity of inflammatory cells at the site of the lesions
in the latter strain. These effects apparently depend on an
absolute rather than a quantitative complement deficiency, as
female mice, which have significantly lower concentrations of
serum C5 than males, are markedly more resistant to infection
(19, 108, 271). Although a deficiency in C5 would be expected
to have similar consequences in different tissues and organs,
the effect is most dramatic in the kidney (Table 4). A/J and
DBA/2 mice, both C5 deficient, showed the highest colony
counts in the kidney after sublethal challenge (17), but the
kinetics of growth and clearance were similar to those in other
strains. The fungal burden in the kidney of AKR mice, which
also lack C5, was less than that in A/J and DBA/2 mice but
greater than in C5-sufficient strains. These data suggest that
mortality in A/J and DBA/2 mice is related to an unusual
susceptibility of the kidney to colonization by C. albicans as-
TABLE 4. Patterns of susceptibility to C. albicans infection
of inbred strains of mice
Strain H-2type
C5
allele Mortality
Brain
damagea
No. of
colonies
in kidney
Antibody
isotypeb
Immuno-
dominant
antigen(s)b
(kDa)
A/J a 0 High Mild High ? ?
AKR k 0 Moderate Severe Low IgG2a 87, 96, 138
BALB/c d 1 Low Mild Low IgG1 48
CBA/CaH k 1 Moderate Severe Low IgG2a 87, 96, 138
DBA/1 q 1 Low Mild Low ? ?
DBA/2 d 0 High Mild High IgG1 48
a Tissue damage was evaluated on the basis of the size and severity of abscesses
in the brain, which is the organ that is most susceptible to infection and in which
the lesions are most obvious.
b Data extracted from Constantino et al. (84).
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sociated with tissue-specific differences in host protective
mechanisms.
Summary. The discrepancies between measures of infection
within and between strains can be interpreted as reflecting a
hierarchy in the innate susceptibility to colonization and in the
efficacy of the protective host response of different tissues and
organs. At very low challenge doses, differences in the fungal
load are seen only in the most susceptible organs, but as the
inoculum is increased, discrepancies between organs and
strains become apparent. Furthermore, if the excessive mor-
tality of strains such as DBA/2 and A/J is caused by an accu-
mulation of Candida organisms in the kidney, leading to renal
failure, then survival may be increased by augmentation of
local phagocytic defense mechanisms. However, this gross ef-
fect may not necessarily be linked to or reflect protective
events occurring in other tissues.
HOST RESPONSE TO INFECTION
Role of Phagocytic Cells
PMNL. In the presence of fresh normal serum, mouse pe-
ripheral blood leukocytes and peritoneal macrophages ingest
viable C. albicans blastoconidia at the same rate, but leuko-
cytes kill intracellular yeasts more effectively than macro-
phages (172). In concordance with the situation in human
candidiasis, an analysis of granulocytopenic and monocytope-
nic mice has confirmed that granulocytes rather than mono-
cytes or exudate macrophages play a dominant role in the early
host response against systemic C. albicans infection (337).
There was little difference in functional activity between mouse
PMNL isolated from the blood and those elicited by inflam-
matory stimuli such as caseinate and proteose-peptone (58);
however, the latter display significantly greater candidacidal
activity than those elicited by thioglycolate. In both murine and
human PMNL, the most efficient system for the killing of C.
albicans yeasts appears to be the myeloperoxidase-hydrogen
peroxide-halide pathway. The amount of hydrogen peroxide
released by mouse PMNL cultured with opsonized or unopso-
nized killed blastospores was proportional to the number of
yeasts to which the cells were exposed (153), but the converse
was found after incubation with viable organisms, even though
the PMNL produced a stronger metabolic burst after stimula-
tion. Thus, it appears that live blastospores are able to alter or
inhibit the release of hydrogen peroxide by the phagocytic
cells. Initiation of the oxidative metabolic burst and hydrogen
peroxide production by the PMNL was found to be a property
of the C. albicans mannan (92) and occurred via a mannose-
inhibitable reaction pathway.
On the other hand, PMNL activated by Blastomyces derma-
titidis antigen in vivo respond not only to this fungus but also to
C. albicans by an increased oxidative burst and significantly
enhanced killing (61), suggesting that optimal phagocytosis is
attained in association with antigen-driven immunological re-
activity. This is now widely recognized as being due to activa-
tion of the cells in vivo by cytokines produced by macrophages
or other leukocytes. As in humans, both mouse PMNL (231)
and macrophages (59, 60) can be activated for Candida killing
in vitro by IFN-g and other T-cell-derived cytokines.
Macrophages. Macrophages, too, make an important con-
tribution to the clearance of Candida infections, and his-
topathological studies clearly indicate that an abundance of
tissue phagocytes can preserve various organs from overt in-
fection. For example, after intravenous injection in mice, the
majority of the inoculum lodges in the liver and lungs (21, 251),
yet these organs rarely sustain even minor damage, probably
because of their large populations of resident phagocytes. In
pulmonary candidiasis, a rapid accumulation of neutrophils in
the lungs is essential for complete clearance of the yeast (193,
242), but studies with immunosuppressed mice showed that
alveolar macrophages are required for both clearance and in-
hibition of dissemination of C. albicans from the lungs (301).
Resident alveolar macrophages were highly efficient in killing
Candida blastospores in vitro (300), although a comparison of
inbred strains showed that this effector activity was a property
of macrophages from mice bred in the C57BL/6 background.
There is, however, considerable heterogeneity in the effector
function of macrophages derived from different anatomical
sites. The candidastatic activity of macrophages freshly isolated
from spleen was equivalent to that of Kuppfer cells and alve-
olar macrophages (96), while that of peritoneal macrophages
was minimal. When cell populations from these same organs
were matured in vitro in the presence of M-CSF, only macro-
phages from liver and spleen displayed significant candida-
static activity. Neither fresh nor differentiated macrophage
preparations were as effective in inhibiting Candida growth as
were cells derived from bone marrow after 3 days in liquid
culture in the presence of M-CSF. The effector cells killed
Candida blastospores by an extracellular mechanism and also
displayed cytotoxic activity against NK-sensitive but not NK-
resistant cell lines. These and previous studies (34, 95) suggest
that the effector cell is a monocyte at an early stage of differ-
entiation, and this may account for the failure to observe en-
hanced candidastatic activity after treatment of the effector
cells with IFN-g (96).
Nonspecific activation of macrophages, for example, by My-
cobacterium bovis BCG purified protein derivative (BCG/PPD)
in vitro, increases killing of phagocytosed C. albicans and in-
hibits the intracellular formation of germ tubes (338). In vivo,
the number of Candida organisms in the kidney, spleen, and
liver after intravenous injection is significantly lower in BCG/
PPD-treated mice than in control mice. Augmentation of Can-
dida killing was also obtained by preincubation of exudate but
not resident macrophages with M-CSF (176). Although M-CSF
induces exudate macrophages to produce IFN-a/b, the augmen-
tation of candidacidal activity could not be blocked by an an-
tiserum against IFN-a/b. In contrast, the candidacidal activity
of resident peritoneal macrophages was enhanced by pretreat-
ment with IFN-g for 24 h (351), and the enhanced activity cor-
related with increased acidification of the phagolysosomes, sug-
gesting that it was mediated by a proteinaceous substance(s).
Mouse peritoneal and splenic macrophages treated with
IFN-g in vitro expressed high candidacidal activity (75) that
correlated with increased concentrations of nitrite in the cul-
ture supernatants. In these experiments, fungal killing and
nitric oxide secretion by the activated macrophages were in-
hibited in a dose-dependent manner by IL-4 and IL-10, either
separately or in combination. Peritoneal cells from mice in-
fected intravenously with C. albicans showed an increase in
nitric oxide synthesis that corresponded with the candidacidal
activity of the cells (268), and nitric oxide has also been im-
plicated in the resistance of mice with the severe combined
immunodeficiency syndrome (scid mutant mice) to mucosal
candidiasis (341). There is not, however, a direct correlation
between nitric oxide production and Candida killing (340).
These authors suggested that nitric oxide was candidastatic
rather than candidacidal and was associated with or induced
other macrophage candidacidal mechanisms. This apparent
discrepancy may be associated with the different susceptibili-
ties of yeast and hyphal growth forms to nitric oxide-mediated
macrophage cytotoxicity (53).
The role in pathogenicity of the dimorphic or, more cor-
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rectly, pleiomorphic (244) growth forms of C. albicans is still
imperfectly understood, but there is increasing evidence that
the yeast and hyphal forms not only differ in their susceptibility
to killing and macrophage proteolytic activity (52) but also
elicit functionally different responses from macrophages and
macrophage cell lines. A cloned bone marrow-derived macro-
phage cell line responded to the hyphal form but not to the
yeast form by an increase in TNF-a production that was not
dependent on ingestion of the fungus by the macrophage (54).
Neutralization of the TNF by the use of a polyclonal antibody
resulted in a time-dependent decrease in TNF transcripts (51),
showing that TNF was able to regulate its own production. It
also influenced the synthesis of other cytokines by the macro-
phages. A macrophage cell line derived from the peritoneum
also produced TNF after stimulation with hyphae but not
yeasts, whereas a line from the lung responded to both (55).
Although cells of microglial origin killed Candida organisms as
efficiently as cells from other anatomical regions, they did not
produce TNF after activation with either growth form. This
suggests that secretion of TNF-a, because of its deleterious
effects, may be under much tighter regulation in the brain than
in other tissues.
Macrophages freshly isolated from tissues of mice showed
patterns of responsiveness similar to those of the macrophage
cell lines. Both resident and thioglycolate-elicited peritoneal
macrophages produced TNF in response to stimulation with
the hyphal but not the yeast form of the fungus (56), whereas
splenic macrophages and PMNL responded to both, and bone
marrow-derived macrophages responded to neither. Alveolar
macrophages were also triggered to produce TNF-a by a C.
albicans mannan (137). These observations indicate that the
path taken by the developing immune response may be deter-
mined to some extent by the morphogenetic status of the
fungus at the time that it interacts with the macrophage or
antigen-presenting cell and the anatomical site where these
early interactions occur.
Role of NK and LAK Cells
Although NK cells are able to kill Cryptococcus neoformans
(152) and some other fungi (194), there is little evidence that
they have any direct or indirect role in recovery from Candida
infection in mice. Beige mutant mice, which are deficient in
NK cells, develop more severe lesions in the brain and other
tissues than their heterozygous littermates, but the severity of
the lesions is independent of the magnitude of the NK defect
(26) and is probably related to some functional defect in the
PMNL in the homozygous mice (35). Furthermore, scid mu-
tant mice, which are deficient in both T and B cells, display no
enhanced susceptibility to infection after depletion of NK cells
by treatment with anti-asialo-GM1 (143), and conventional
mice infected with an attenuated strain of C. albicans and
depleted of NK cells by treatment with a monoclonal antibody
showed no changes in the development of resistance to rein-
fection or in Th cell function (285).
Nevertheless, C. albicans does stimulate NK cell activity. A
single intraperitoneal injection of inactivated Candida yeasts
induces a subset of cells sensitive to the asialo-GM1-specific
antibody, which displays cytotoxic activity against YAC-1 cells
(202). Multiple injections, on the other hand, generate a pop-
ulation of nonadherent, nonphagocytic, large granular lympho-
cytes that kill both NK-sensitive and NK-resistant tumor target
cells in vitro (303) and display phenotypic and functional prop-
erties similar to those of LAK cells generated in vitro. Analysis
of cytokine mRNA production by the peritoneal exudate cells
at the conclusion of the course of injections (294) revealed
IL-1b, IL-2, IL-6, IL-10, IFN-g, and TNF-a but not IL-12. IL-2
was expressed and sustained at high levels; however, there was
only weak, transient expression of mRNA for the other cyto-
kines. Administration of a single dose of recombinant human
IL-2 (rhIL-2) to the Candida-treated mice increased NK cell
activity but did not activate LAK-like effectors (305), whereas
rhIL-2 given in combination with the inactivated yeast strongly
increased both the cellularity of the peritoneal exudate and the
cytotoxic activity of the peritoneal NK and LAK cells (304).
These LAK-like cells, induced either in vivo or in vitro, exhibit
high levels of activity against C. albicans hyphae (302). The
biological relevance of this phenomenon is unknown, although
it has been suggested that it may represent a second level of
host defense against C. albicans hyphal forms in immunosup-
pressed mice (302).
Effect of Cytokines In Vivo
As recombinant cytokines have become more readily avail-
able, they have increasingly been used to modify the host
response to C. albicans infection in vivo. However, the effects
of treatment have not always been consistent and are some-
times difficult to interpret.
Administration of recombinant IFN-g (rIFN-g) to infect-
ed mice was associated with significantly improved survival
after lethal challenge (267), and this correlated with an in-
crease in the candidacidal activity of peritoneal macrophages
and Kupffer cells after treatment with IFN-g in vitro. Another
study of the effect of rIFN-g in vivo showed a reduction in the
growth of C. albicans in the kidneys, spleen, and liver of mice
after treatment from 1 day before to 3 days after infection
(190). In this case, the enhanced resistance of the treated mice
correlated with a significant increase in the capacity of periph-
eral blood and peritoneal exudate granulocytes to kill C. albi-
cans in vitro. In a different experimental model, treatment of
mice with IFN-g actually decreased resistance to challenge
(136), although boosting immune responsiveness by immuni-
zation overrode the suppressive effects. Similarly, poly(I z C), a
potent inducer of interferons in vivo, increased the suscepti-
bility of CB-17 scid mice to acute systemic candidiasis and to
systemic candidiasis of endogenous origin (164). The enhanced
susceptibility was abrogated by in vivo treatment with antibod-
ies to IFN-a, -b, and -g. The effect was independent of NK
cells and was attributed to an impairment of the candidacidal
activity of macrophages.
Cytokines can also enhance resistance to infection by stim-
ulating the production of phagocytic effector cells. Administra-
tion of recombinant human IL-1 (rhIL-1) to mice did not
significantly elevate blood neutrophil concentrations but sub-
stantially increased the number of PMNL within the tissues
without causing detectable changes in macrophage numbers
(191). The bactericidal capacity of splenocytes rose in parallel
with PMNL accumulation. Comparable doses of TNF also
enhanced killing of Listeria monocytogenes in vivo, but in con-
trast to IL-1, TNF significantly depressed peripheral blood
neutrophil counts and inhibited the accumulation of neutro-
phils in the spleen. Other experiments confirmed that prophy-
lactic treatment with rhIL-1b enhanced the resistance of mice
to systemic C. albicans infection (253).
In mice myelosuppressed by cyclophosphamide, subcutane-
ously administered rGM-CSF increased the number of precur-
sor cells in bone marrow and caused a profound neutrophilia
that protected the mice against lethal infection with the yeast
(217). Prophylactic treatment with human G-CSF (hG-CSF)
conferred significant protection against systemic C. albicans
infections in cyclophosphamide-treated (211) but not in corti-
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sone-treated mice (260). G-CSF increased production of neu-
trophils by bone marrow in vivo (132), thus augmenting resis-
tance to challenge with C. albicans and other fungal pathogens
(132, 335). It also acted synergistically with stem cell factor to
stimulate granulocyte recovery and protect against lethal in-
fection with C. albicans in cyclophosphamide-treated mice
(321). However, localized candidiasis in neutropenic mice did
not respond to hG-CSF (260).
There are conflicting reports on the role of M-CSF in mu-
rine candidiasis. After infection in [BALB/cCr 3 DBA/2Cr]F1
hybrid mice, the number of monocytic precursor cells in the
bone marrow increased, and both serum and tissue concentra-
tions of M-CSF were elevated (73). Administration of the
purified cytokine to infected mice reduced the number of col-
onies recovered from the organs and extended survival time.
The beneficial effects in vivo correlated with an enhanced can-
didacidal activity of macrophages treated with M-CSF in vitro.
On the other hand, treatment of C3H mice with M-CSF, either
before or after intravenous infection with C. albicans, exacer-
bated the disease, causing a doubling of the rate of weight loss
and leading to significantly earlier death (159). This result was
interpreted as evidence favoring a major role for macrophages
in the pathology of the disease, but recent results (see below)
have raised the possibility that alterations in the cytokine mi-
lieu may have favored the development of different Th subsets
in the different mouse strains.
It is, of course, not possible to resolve these conflicts without
conducting experiments that control for variables such as mouse
strain and the ‘‘virulence’’ of the yeast, but the discrepancies em-
phasize that the effects of administration of any individual cyto-
kine in vivo will markedly influence and be influenced by the host
microenvironment (Fig. 1). Furthermore, the introduced cyto-
kine may enhance or inhibit the production of others, distort-
ing the normal response to the infection and making unequiv-
ocal interpretation of the results very difficult. These issues will
be considered at greater length within the context of cytokine
regulation of the T-lymphocyte response to the infection.
IMMUNE RESPONSES TO C. ALBICANS
In general, experimental results in mouse models have sug-
gested that cell-mediated and humoral types of immunity play
major and minor roles, respectively, in host defense against C.
albicans (173). However, in evaluating the relative contribu-
tions of the various effector mechanisms, it is crucial to make
a clear distinction between those that are responsible for re-
covery from an initial (primary) infection and those that me-
diate protection from reinfection. Specifically, the presence of
cell-mediated immune responses in an immune animal does
not necessarily indicate that these are the cause of the en-
hanced resistance to rechallenge (28, 29).
Cell-Mediated Immune Responses
Establishing a role for T cells and cell-mediated immunity in
Candida infections has been difficult, and early results were con-
troversial. Although neonatally thymectomized mice showed
an increased susceptibility to C. albicans infection (297), an
effect of T-cell deficiency was not observed in adult thymecto-
mized, irradiated, bone marrow-reconstituted AT X BM mice
(140) or in nude mice (90, 277). The resistance of AT X BM
and nude mice can probably be attributed to nonspecific acti-
vation of the monocyte/macrophage system (79, 364) and ap-
pears to be short-lived, as both strains have been shown to be
substantially more susceptible than controls in the later stages
of the infection (227, 311).
Mice treated with a Thy-1.2-specific monoclonal antibody in
vivo show a significant reduction in the efficiency of clearance
of Candida organisms from the spleen (9), confirming that T
lymphocytes contribute to recovery from primary infection,
and these findings are consistent with the further demonstra-
tion that host responsiveness in congenic resistant mice is reg-
ulated by genes within the MHC (9, 10). Corroborative evi-
dence was provided by the transfer of a Candida-specific T-cell
line into sublethally irradiated mice (309); the T-cell line con-
ferred resistance against primary systemic challenge. There is
evidence that both CD41 and CD81 cells contribute to the
host response against infection (13, 76, 83), and the general
thrust of results to date indicates that a central element of host
resistance is the production of cytokines by Candida-specific T
cells.
The specificity of both CD41 and CD81 T lymphocytes is
defined during differentiation in the thymus, and this organ has
also been thought to be the source of a family of hormone-like
products (thymosins) important to the maintenance and func-
tioning of the immune system. Therefore, early attempts at
modulating and enhancing host resistance to C. albicans in-
volved treatment of mice with these thymic ‘‘hormones.’’
Effect of Thymosin
Thymosin fraction V is a partially purified extract of calf
thymus containing a complex mixture of 40 to 60 peptides with
molecular masses of less than 10 kDa. Several of its compo-
nents possess immunopotentiating activity and mediate a vari-
ety of effects on cell-mediated immune responses.
In the present context, thymosin fraction V has been used to
modulate host responses to C. albicans in inbred strains of
mice that are either resistant or susceptible to intravenous
challenge. The different strains showed a direct correlation
between colony counts in the kidney and levels of macrophage
inhibitory factor and IFN-g released into the circulation (238).
FIG. 1. Cytokine responses of immune and inflammatory cells. Only those
cytokines presently known to be relevant to C. albicans infection are shown. The
arrows pointing inward indicate cytokines that have an effect on the cell; those
pointing outward indicate cytokines produced by the cell.
VOL. 59, 1995 CYTOKINES IN IMMUNITY TO C. ALBICANS 655
Administration of thymosin fraction V beginning on the day of
infection greatly enhanced the resistance of the susceptible
strains but increased levels of infection in the resistant strains
(296). In parallel with this, cytokine production by the suscep-
tible and resistant strains was increased and reduced, respec-
tively (238). In contrast, treatment with thymosin factor V
increased specific DTH responses of resistant mice but had no
effect on delayed footpad reactions in the susceptible strains
(296). The impairment of cell-mediated immune responses in
mice made diabetic with alloxan could also be reversed by
thymosin factor V (298).
Thymosin a1 was the first of the thymic peptides to be
purified to homogeneity (327) and showed many of the bio-
logical properties of thymosin fraction V. Treatment of mice
with thymosin a1 conferred protection against lethal intrave-
nous infection with C. albicans if administered before but not
after challenge (45) and also prevented the increased suscep-
tibility to infection caused by cyclophosphamide. The protec-
tive effect was associated with an increase in both the numbers
and the candidacidal activity of circulating PMNL in the pe-
ripheral blood (43). This therapeutic approach was found to be
effective when used either alone or in combination with flu-
conazole in ameliorating systemic candidiasis in mice immu-
nosuppressed by treatment with morphine (99). The protective
effect of thymosins in vivo is probably mediated by their ability
to stimulate the production of a variety of different cytokines
(30, 158, 186).
The mechanisms of action of the various thymosins have not
yet been elucidated. Thymosin a1 has been shown not to be a
hormone (327) but is instead a breakdown product of an abun-
dant cellular protein called prothymosin, which exhibits many
of the same biological and immunological properties but whose
primary function appears to be the regulation of cellular pro-
liferation. Thymosin b4 is another well-characterized constitu-
ent of thymosin fraction V that also exhibits immunoregulatory
activities, but these too may be secondary to its actin-seques-
tering properties and potential role in the regulation of the
microfilament system (225). The whole issue is rendered much
more complex by evidence that the thymosins function as im-
munotransmitters (146), conveying signals both directly to leu-
kocytes and indirectly to the immune and other homeostatic
systems via neuroendocrine and autonomic nerve pathways.
Thus, they may function not only to stimulate specific effector
mechanisms but also to coordinate the whole-body response to
infection or disease.
Candidiasis in Mutant Mice
Further evidence consistent with an important role for T
lymphocytes in murine candidiasis comes from studies of mu-
cosal infections in germfree athymic mice. After colonization,
lymphocyte proliferation and footpad responses to Candida
antigens were demonstrable in the nu/1 control mice, and
these manifestations of cell-mediated immunity correlated
with the clearance of Candida hyphae from the dorsal surface
of the tongue and from the stomach (37). Conversely, nu/nu
mice could not clear mucosal candidiasis and did not exhibit
Candida-specific lymphocyte proliferation or footpad swelling.
The nu/numice did not develop a progressive systemic disease,
indicating that ‘‘nonimmune’’ mechanisms were sufficient to
prevent dissemination from the gastrointestinal tract in this
model.
Investigations of the effect of the combined beige (bg/bg) and
nude (nu/nu) mutations on the development of systemic can-
didiasis after gastrointestinal colonization (64, 65) revealed
that only the beige athymic (bg/bg nu/nu) mice developed se-
vere infections. In contrast, bg/bg mice, nu/nu mice, and bg/bg
nu/nu mice were all resistant to naturally occurring vulvovag-
inal candidiasis (63). Candida-colonized beige euthymic but
not beige athymic mice developed C. albicans-specific antibody
and cell-mediated immune responses. The susceptibility to
candidiasis of bg/bg mice is probably attributable not to a de-
ficiency of NK cells (26) but to some reduction either in the
effector function of the PMNL (168, 189) or in the ability of
macrophages to respond to activation by cytokines (339).
These data suggest that a combination of defects in both
phagocytic cell function and cell-mediated immune responses
predispose mice to severe mucosal and systemic candidiasis of
endogenous origin.
Mutant scid mice lack functional T and B cells, but neither
conventional (201) nor germfree (38) animals display any un-
usual susceptibility to intravenous challenge with C. albicans.
However, gastrointestinal candidiasis was more easily estab-
lished in scid mice than in controls (234), and when they were
treated with a monoclonal antibody to murine granulocytes
(anti-Gr-1), with silica, or with carrageenan, scid mice showed
enhanced susceptibility to acute systemic candidiasis, dissemi-
nated candidiasis of endogenous origin, and orogastric candi-
diasis (165). These data are consistent with clinical studies that
point out the important role played by granulocytes in host
defenses against Candida infections; nevertheless, macro-
phages (166) as well as T and B cells (165) have also been
shown to contribute to the control of orogastric and dissemi-
nated candidiasis of endogenous origin.
Genetic Regulation of Host Immune Responses
Inbred strains of mice that develop severe (type I) or mild
(type II) lesions in the tissues [21] can be independently cate-
gorized as producing high or low immune/inflammatory re-
sponses in the popliteal lymph nodes, respectively, after chal-
lenge with viable C. albicans blastospores. Thus, CBA/H mice
are type I and low responders, whereas BALB/c mice are type
II and high responders (9). During primary infection with C.
albicans, the magnitude of T-lymphocyte responses in the
draining lymph nodes is determined by genes within the mouse
MHC (9), and these host immune/inflammatory responses are
controlled, at least in part, by class I MHC genes (10). How-
ever, in comparison to the BALB/c strain, congenic resistant
BALB/k (H-2k) mice show a significantly reduced inflamma-
tory response in the popliteal lymph node after footpad immu-
nization (9), even though they exhibit mild (type II) lesions.
Analysis of lymph node responses in (BALB/c3 BALB/k)F1
hybrid mice shows that low responsiveness is dominant (23);
however, a background gene(s) present in B10 congenic resis-
tant strains appears to either modify or override the MHC-
linked regulation of host responses (9). The regulatory effect of
MHC genes is substantially weaker than that of background
genes, which generally determine the outcome of infection in
infectious disease models; but MHC genes have been linked to
diseases in which there is a significant immunopathological
component (365). Nevertheless, in Candida infection, the mag-
nitude of primary T-lymphocyte responses does not correlate
with the severity of lesions in different inbred strains of mice,
suggesting that the MHC associations influence other aspects
of the host immune response.
Cytokine Production by T-Cell Subsets
The major function of the T lymphocytes in Candida infec-
tion is the production of cytokines that enhance the candi-
dacidal activity of mononuclear and polymorphonuclear effec-
tor cells. T cells can be divided into two functionally distinct
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subpopulations on the basis of the presence or absence of CD4
and CD8 antigens or the cell surface, and in the mouse at least,
CD41 Th cells can be separated into distinct groups according
to their patterns of cytokine production.
Originally, two main subgroups were identified—Th1 cells,
secreting IL-2 and IFN-g, and Th2 cells, secreting IL-4 and
IL-5 (233). The mode of antigen presentation influenced the
development of the Th subsets, in that antigen presentation by
splenic B cells favored the Th2 subpopulation, while presenta-
tion by macrophages favored the generation of Th1 cells (133).
In a mouse model of leishmaniasis, clones belonging to the
different Th subsets were found to respond to different parasite
antigens and to subserve different roles (307), and there was
reciprocal expression of mRNAs for IFN-g and IL-4 in the
spleen and lymph nodes of Leishmania-infected C57BL/6 and
BALB/c mice, which are resistant and susceptible, respectively,
to infection (150). However, a survey of inbred strains (230)
has shown that, along the spectrum of cutaneous leishmaniasis,
IL-4 is a reliable indicator of disease but IFN-g does not
correlate with resistance.
There has been a degree of controversy about the relevance
in vivo of a classification based on T-cell clones, in that pat-
terns of cytokine production by individual alloreactive T cells
are essentially random (179) and there exist clones that coex-
press cytokines ‘‘diagnostic’’ of both Th subsets. However, the
demonstration that human CD41 lymphocytes also develop
stable Th1 and Th2 cytokine profiles (281) suggests that the
phenomenon is general, and recent data (255) have shown that
there are differences in cytokine receptor signaling pathways
between committed cells of the Th1 and Th2 subsets. The
implication from these studies at the clonal level is that infec-
tious agents, such as Leishmania spp., induce an immune re-
sponse that exhibits, at the population level, a dominance of T
cells expressing a Th1- or Th2-like pattern of cytokine produc-
tion.
This paradigm has had important ramifications in the anal-
ysis of Candida infections, particularly as cytokines typical of
the two subsets not only augment or depress the function of
phagocytic cells but also regulate crucial pathways in the im-
mune response.
Cellular Immune Responses in Mucosal Infection
Candida infection of the oral mucosa in mice triggers an
inflammatory response and stimulates cellular immunity (192).
Following a second topical challenge with C. albicans, the
infection was barely detectable, and a typical DTH reaction
occurred at the site. Similar effects were seen after gastroin-
testinal infection of infant mice (108), in that colonization
primed the mice for enhanced DTH responses and protected
adult mice from systemic challenge.
The influence of the genetic background of the mice on the
development and resolution of mucosal infection was exam-
ined in BALB/c and DBA/2 mice, which carry the same MHC
haplotype (H-2d). After topical administration of C. albicans to
the oral mucosa, both strains showed an increase in MAC-11
cells and a similar recruitment of CD41 and CD81 T lympho-
cytes into the mucosal tissue (78). Infection was associated
with an influx of g/d T cells on day 3 in BALB/c mice but on day
5 in the DBA/2 strain, which coincided with a sudden decrease
in the number of viable organisms recovered from the mucosal
tissue. The two strains also differed in the sequelae of infec-
tion, in that systemic immunity, demonstrable as Candida-
specific DTH responses, developed in the DBA/2 but not in the
BALB/c mice. There is a curious parallel here with the expres-
sion of strong antibody-mediated protective responses in CBA/
CaH mice, which develop severe tissue damage, compared
with a less obvious effect in the more resistant BALB/c strain
(22).
A functional role for the g/d T-cell subset was also demon-
strated by intraperitoneal infection of immunocompetent mice
and knockout mice (mice with targeted gene deletions) with C.
albicans. This resulted in a steady accumulation of both g/d T
cells and macrophages in the peritoneal cavity (169). The g/d T
cells produced IFN-g, which enhanced macrophage candi-
dacidal activity and nitric oxide production. This T-cell subset
may represent an important element in host resistance, as
specific depletion of these cells increased the susceptibility to
mucosal candidiasis of both immunocompetent and T-cell-de-
ficient (nu/nu) mice. Nevertheless, a/b T cells have also been
implicated in host defense. Previous experiments by the same
group had demonstrated that mucosal C. albicans infection in
the alimentary tract of multiply immunodeficient (bg/bg nu/1)
mice induced a population of lymphocytes in both the Peyer’s
patches and spleen that proliferated and produced IL-2 in
response to stimulation with Candida antigens (66). Candida-
reactive lymphocytes were not found in mice homozygous for
the nude mutation (bg/bg nu/nu), and these animals were un-
able to clear the yeasts. The presence of these lymphocytes
correlated with clearance of the yeast from the esophagus and
tongue. Depletion of CD41 cells increased susceptibility, but
neither IL-2 nor IFN-g could be identified as a mediator in this
experimental system.
Other models of mucosal infection have placed a greater
emphasis on the function of cytokines associated with the dif-
ferent Th subsets. Although DBA/2Cr mice develop fatal dis-
seminated candidiasis after intravenous infection with the avir-
ulent PCA-2 vaccine strain (284), intragastric colonization of
these mice with the virulent CA-2 strain was associated with
the induction of strong cell-mediated immune responses of the
Th1 type and eventual clearance of the infection (44). In
BALB/c mice, which are resistant to systemic challenge with
the PCA-2 yeast strain (284), gastrointestinal colonization with
the CA-2 yeast strain resulted in the production of both Th1-
type (IFN-g) and Th2-type (IL-4 and IL-5) cytokines by CD4
1
cells from Peyer’s patches and mesenteric lymph nodes at a
time when the yeasts were being cleared from the intestine
(74). Administration of recombinant IL-4 or IL-10 to the mice
exacerbated the course of infection (331) and induced produc-
tion of high levels of these same cytokines by CD41 lympho-
cytes from the Peyer’s patches. In contrast, enhancement of
mucosal Th2 responses by oral administration of cholera toxin
did not modify the course of the disease, but intravenous treat-
ment of the infected mice with soluble IL-4 receptor, which
enhances Th1-type cytokine responses (261), increased gastro-
intestinal clearance of the yeasts.
Vaginal Candida infection in CBA/J mice induced systemic
cell-mediated immunity within 2 weeks (126), but in vitro anal-
ysis of cytokine production by lymph node cells detected pre-
dominantly IL-2 and IFN-g, with no IL-10, and only small
elevations of IL-4 in the later stages of infection. Rather un-
expectedly, the course of primary vaginal candidiasis was un-
affected by preinduction of either systemic immunity or Can-
dida-specific suppressor cells (127), even though the latter
significantly reduced the DTH responses elicited by the vaginal
challenge. However, when mice in which Th1-type systemic
responses elicited by an initial vaginal infection were given a
second vaginal inoculation, they developed anamnestic DTH
responses and showed reduced colonization of the vagina com-
pared with mice with primary infections (123). Although severe
oral candidiasis can occur in association with an immunodefi-
ciency characterized by a reduction in CD41 T cells in the
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absence of human immunodeficiency virus infection (138, 250),
monoclonal antibody depletion of CD41 and CD81 cells had
no effect on primary or secondary vaginal candidiasis in mice
(128).
The general conclusion from these results is that resistance
to mucosal infections is determined by phagocytic mechanisms,
the activity of which is augmented or reinforced by Th1-type
cytokines. Although there is some evidence of a link between
the mucosal and systemic immune responses, specific pathways
have not yet been identified. Cross-regulation of Candida-
specific immune responses has been examined in greater detail
using models of systemic infection.
Cytokines in Vaccine-Induced Resistance
Infection of mice with an attenuated strain of C. albicans
(PCA-2) incapable of yeast-mycelium transitions was found to
increase resistance against a subsequent challenge with the
virulent parental strain (CA-2) (46). The protection induced
was nonspecific and depended on the inoculation of sufficient
organisms to establish a long-lasting chronic infection without
causing death (344). Anti-infectious activity was directly cor-
related with macrophage activation (46, 344) and appeared to
be independent of the function of T lymphocytes, as the effects
could be reproduced in athymic mice (47). After treatment
with PCA-2, high levels of GM-CSF, TNF-a, IL-1, and IFN-g
were detected in the serum and in the supernatants of spleen
cell cultures (342), and cytokine production was also correlated
with the expression of microbicidal activity in vivo.
In normal (euthymic) mice, infection with the PCA-2 strain
elicited strong DTH reactions to C. albicans concomitantly
with the expression of candidacidal activity by activated splenic
macrophages (76). The DTH reactivity was attributable to
CD41 T lymphocytes that produced IFN-g and GM-CSF in
vitro. Elimination of the CD41 cells by treatment of the mice
with a monoclonal antiserum abrogated the DTH response
and increased the burden of PCA-2 yeasts in the kidneys (76)
but did not alter the survival of mice challenged with strain
CA-2. This result is consistent with previous work (9) showing
that depletion of T lymphocytes from sublethally infected mice
impairs clearance of the yeast partially but not completely and
confirms the importance of activated macrophages in augment-
ing resistance against lethal challenge in this experimental
model (46, 47).
The contribution of the CD41 and CD81 T-cell subsets to
the development of immune responses and protection against
lethal challenge after priming with the attenuated PCA-2 strain
was evaluated by administration of antibodies to CD4, CD8, or
IFN-g in the early stages of infection (283). Treatment with
antiserum to either CD4 or IFN-g modified the course of the
disease and prevented the development of resistance to rein-
fection, but mice given a combination of both antisera devel-
oped a fatal candidiasis caused by overgrowth of the attenu-
ated vaccine strain. In vitro, spleen cells from PCA-2-primed
mice produced high levels of IFN-g in response to stimulation
with Candida antigen (77), and this activity was abolished only
by complement-mediated lysis of the responder population
with antisera to both CD41 and CD81 lymphocytes. Purifica-
tion of CD41 and CD81 cells by positive selection confirmed
that both produced IFN-g provided that appropriate accessory
cells were present during in vitro stimulation with the yeast.
Resistance to challenge with the virulent CA-2 yeast strain
induced by prior infection with the PCA-2 strain was impaired
either by depletion of CD41 and CD81 cells or by treatment of
the primed mice with a polyclonal antiserum to IFN-g (77).
These two studies demonstrated that CD41 T cells play the
dominant role in the early evolution of protective responses
induced by infection with the avirulent yeast strain but that
both CD41 and CD81 cells are involved in the expression of
acquired resistance to subsequent challenge. IFN-g is involved
in both the early and late phases of the response. Further
analysis of this model has focused on the role of the CD41
Th-cell subsets in the evolution of host responses.
Th Subsets in Candida Infection
When two agerminative variants of C. albicans produced by
chemical mutagenesis were used to elicit anti-infectious pro-
tection, different responses were obtained in vivo and in vitro.
One variant induced significant resistance against challenge
with the virulent parental strain that was associated with DTH
responses in vivo and increased the fungicidal activity of mac-
rophages in vitro (289). The other variant was not protective.
The protective variant induced CD41 lymphocytes that re-
leased large amounts of the Th1 cytokines IFN-g and IL-2,
whereas CD41 cells generated by immunization with the non-
protective variant produced the Th2 cytokines IL-4 and IL-6.
The connection between Th type and disease outcome was
elegantly demonstrated by Romani et al. (282), who showed
that a single injection of a monoclonal antibody to IFN-g in
conjunction with the PCA-2 yeast strain caused a change in the
cytokine profile from a Th1-type, associated with protection, to
a nonprotective Th2-type response.
Similar reciprocity between Th1 and Th2 cytokine profiles
and induction of resistance or progression of the disease was
observed in BALB/cCr and DBA/2Cr mice after infection with
the PCA-2 vaccine strain of C. albicans (284). As is the case in
the (BALB/cCr 3 DBA/2Cr)F1 hybrid (76, 342), BALB/cCr
mice developed resistance to reinfection associated with Th1
responses, whereas DBA/2Cr mice exhibited a progressive dis-
ease and showed sustained production of Th2 cytokines by
CD41 cells in vitro (284). However, when the DBA/2 mice
were treated with an IL-10-specific antiserum at the time of
infection, they survived (292). Recovery was associated with
the onset of footpad responses and the development of durable
protection from reinfection. In vitro, the level of expression of
IL-4 and IL-10 mRNAs in CD41 spleen lymphocytes was re-
duced, and macrophages displayed increased production of
nitric oxide after activation by IFN-g. Similarly, when (BALB/
cCr3DBA/2Cr)F1 hybrid mice were infected with the virulent
CA-2 strain of C. albicans and treated with a monoclonal
antibody to IL-4, a high proportion of the mice survived (286).
Disease resolution was evinced by clearance of the yeast from
infected organs and was associated with strong Th1 responses
and the establishment of long-lasting protective immunity. Re-
ciprocal changes in cytokine mRNA levels were seen in CD41
cells, in that there was a decrease in IL-4 mRNA and a corre-
sponding increase in IFN-g transcripts. Identical results were
obtained by treatment of the infected mice with recombinant
soluble IL-4 receptor (261).
Comparison of cytokine responses in mouse-yeast strain
combinations that induce either self-limiting infections and
survival (healer) or chronic disease and death (nonhealer)
showed that IL-4 and IL-10 production correlates with pro-
gressive fatal infection. In both healer and nonhealer combi-
nations, administration of IL-4 or IL-10 accentuated the sever-
ity of infection and led to a progressive dominance of the Th2
pattern of lymphocyte reactivity (331). Secretion of IFN-g pro-
tein by CD41 and CD81 lymphocytes occurred only in mice
with self-limiting infections (288), but high levels of IFN-g
were detected in the serum of mice that succumbed to infec-
tion, thus excluding a defect in the IFN-g response as a factor
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that biased these mice towards a preferential expansion of Th2
cells. In mice that recovered from infection, IL-12 mRNA was
continuously expressed in splenic macrophages, and it was also
required for Candida-specific induction of IFN-g by CD41
cells in vitro. In subsequent experiments, its role in driving Th1
differentiation in vivo was investigated by treating mice with
either the neutralizing antibody or the recombinant cytokine
(287). Mice with self-limiting infections did not develop resis-
tance after neutralization of IL-12 and showed Th2-type re-
sponses. However, when mice suffering from progressive dis-
ease were treated with rIL-12, they did not recover or exhibit
any change in Th profile.
Although healer and nonhealer responses have been linked
to the activities of cytokines that reflect the preferential ex-
pansion of Th1 and Th2 lymphocyte subpopulations, other cy-
tokines play an important role in host resistance and in the
evolution of protective immunity. TGF-b modulates the func-
tion of T and B lymphocytes and was found to be upregulated
in mice with self-limiting infections but downregulated in an-
imals that succumbed to systemic challenge (318). Neutraliza-
tion of TGF-b in vivo did not affect the outcome of primary
challenge in a healer combination, but it compromised the
development of resistance by these mice against a later chal-
lenge with a virulent yeast strain. However, the role of this
cytokine is not clearcut, as treatment of nonhealer mice with
recombinant TGF-b delayed progression of the disease.
The studies described above have demonstrated that the
balance between a Th1- and a Th2-type response is labile and
capable of being influenced by the virulence of the yeast strain
and the genetic context in which infection takes place. Perhaps
not surprisingly, other, extraneous factors can also influence
disease outcome and Th phenotype. For example, outbred
mice made diabetic by treatment with streptozotocin devel-
oped an acute lethal infection after challenge with the low-
virulence PCA-2 strain of C. albicans (232), and the disease
was associated with the production in vitro of a Th2-like cyto-
kine profile by CD41 lymphocytes (221). Unfortunately, the
mechanisms that determine the dominance of the Th2 pheno-
type in this model have yet to be elucidated.
Synergistic Effects of Concomitant Infection
Coinfection of mice with C. albicans and murine cytomega-
lovirus (147) or some bacteria (68) causes a synergistic inter-
action that results in exacerbation of infection and increased
mortality. In a combined murine cytomegalovirus-C. albicans
infection (148), the titers of murine cytomegalovirus in tissues
were unaltered, but the C. albicans infection changed from a
self-limiting to a fatal progressive disease. Similarly, adminis-
tration of Escherichia coli or E. coli lipopolysaccharide to mice
given a lethal inoculum of C. albicans increased kidney colo-
nization and accelerated death (1). In contrast, when various
Staphylococcus aureus isolates were administered to mice in
conjunction with a sublethal dose of C. albicans, the severity of
the bacterial infection increased dramatically (70), especially in
mice receiving S. aureus strains derived from patients with toxic
shock syndrome (69).
S. aureus contains an enterotoxin that belongs to a family of
powerful T-cell stimulants called superantigens, which interact
directly with specific alleles of the Vb chain of the T-cell
receptor (356). Activation by superantigens can lead to clonal
expansion, deletion, or anergy of the target T-cell subset (243).
Treatment of mice with staphylococcal enterotoxin B leads to
the induction of anergy in Vb81 CD41 lymphocytes (177) and
biases the cytokine response towards a Th1 type (39). The
gradual development of anergy in the Vb81 subpopulation
correlates with a decrease in IL-4 and reciprocal increase in
IFN-g production by CD41 lymphocytes (293), accompanied
by an enhanced resistance against lethal systemic challenge
with C. albicans. In contrast, when the mice were primed with
staphylococcal enterotoxin B and challenged with C. albicans
within 24 h, mean survival times were dramatically shortened
(293). The relevance of this latter result to the natural course
of infection is unclear, as coinfection with S. aureus does not
lead to a synergistic enhancement of C. albicans infection (70)
and T cells in the lesions of human patients with oral candidi-
asis do not express the biased T-cell receptor distribution that
would be consistent with the involvement of a superantigen
(310).
In summary, by using combinations of wild-type and aviru-
lent yeast strains in susceptible and resistant strains of mice,
this experimental system has illuminated the pathways by
which characteristic cytokine profiles develop within the Th1/
Th2 paradigm and the ways in which they can be modified by
the use of appropriate reagents (Table 5). Nevertheless, it is
clear that there are anomalies that involve not only the role of
CD41 and CD81 T lymphocytes but also the contributions of
other cytokines.
Immunopathology in Primary Systemic Infection
All of the studies reviewed thus far have found that CD41
lymphocytes are the primary T-cell subset involved in the gen-
eration of cell-mediated immune responses to C. albicans. A
quite different outcome was obtained after treatment of acute
systemic infection in BALB/c mice with monoclonal antibodies
specific for CD41 or CD81 cells (83).
In these experiments, depletion of CD81 cells did not influ-
ence either overall survival or mean survival time, whereas
depletion of CD41 cells significantly enhanced both. Com-
bined depletion of CD41 and CD81 cells significantly length-
ened the mean survival time, although it did not increase the
proportion of animals that survived. These data demonstrated
that CD81 cells could exert a beneficial effect in recovery from
primary infection but that this was overshadowed by a stronger
immunopathologic CD41 response. The protective effect of
CD4 depletion was not associated with functional changes in
phagocytic cells, so it was suggested that lethality might be due
to the production of potentially harmful cytokines, such as
TNF.
Intraperitoneal infection with C. albicans in mice raises lev-
els of endogenous TNF (273) and causes a chronic elevation of
plasma fibrinogen levels without altering other blood parame-
ters. The possible contribution of TNF-a to early death in
acute C. albicans infection was evaluated in BALB/c mice (3).
After administration of 108 blastoconidia, mice died within 12
h. The TNF concentrations in sera from these mice were sig-
nificantly greater than in controls, but pretreatment with a
TABLE 5. Effect of cytokine and anticytokine treatment on
resistance of mice to C. albicans infectiona
Cytokine or anticytokine Effect on resistance
IFN-g ........................................................................... Increased
Anti-IFN-g .................................................................. Decreased
IL-12 ............................................................................ Decreased
Anti-IL-12 ................................................................... Decreased
IL-4 .............................................................................. Decreased
Anti-IL-4 ..................................................................... Increased
IL-10 ............................................................................ Decreased
Anti-IL-10 ................................................................... Increased
a Reproduced with permission from Mencacci et al. (220).
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TNF-a-specific antiserum did not reduce mortality. In con-
trast, mice given murine TNF-a were more resistant to chal-
lenge, indicating that, far from mediating a toxic shock-like
process, TNF-a may enhance phagocytic clearance of the
yeast. In a less aggressive experimental model (198), TNF-a
was first detected in the serum 16 h after infection. Concen-
trations increased progressively and reached peak levels
shortly before death. Administration of a polyclonal antibody
against TNF-a increased colony counts in the tissues and de-
creased survival.
A protective effect of TNF-a was further demonstrated in
normal and granulocytopenic mice (322). During C. albicans
infection, both TNF-a and IL-6 were secreted into the serum
in a dose-dependent manner. Growth of the yeasts in the
kidney was significantly increased in normal mice treated with
a monoclonal antibody against TNF-a, but the fungal burden
in similarly treated granulocytopenic mice was unaffected, sug-
gesting that TNF is essential for granulocyte antifungal activity
in vivo. Somewhat different results were obtained after pulmo-
nary infection in normal and cyclophosphamide-treated mice
(132). The granulocytopenic mice developed high levels of
TNF-a in serum and bronchoalveolar lavage fluid and died
within 48 h, whereas the normal mice survived the challenge
and had very low levels of TNF-a. Administration of G-CSF to
the granulocytopenic mice markedly reduced TNF-a concen-
trations, increased the numbers of granulocytes, and signifi-
cantly prolonged survival.
Clearly, considerable progress has been made in defining the
cytokine-mediated effector pathways that contribute to protec-
tion from lethal systemic infection, but there are certainly
points of conflict between results generated in different exper-
imental systems, and many issues remain to be clarified. How-
ever, the most problematical area in human infection is not
protection against lethal systemic infection, about which there
is now a good understanding, but the issue of susceptibility to
recurrent Candida vaginitis. As detailed above, numerous an-
imal models of mucosal infection have been developed and
characterized, but none have shed light on the defects that may
predispose to the human disease. As recurrent candidiasis is
often associated with unusually severe tissue inflammation
(160), an alternative experimental approach has been used to
analyze host responses in mice that show genetically deter-
mined differences in tissue responses to systemic infection.
The relevance of such a model to mucocutaneous disease
can be questioned, but such qualms are probably groundless
for the following reasons. First, there is considerable evidence
that C. albicans can, under certain conditions, penetrate the
mucosal (especially gastrointestinal) barrier in both normal
humans (187) and unmodified mice (108, 116); second, gastro-
intestinal colonization induces systemic immunity (108, 125);
and finally, chronic mucocutaneous candidiasis is strongly
linked to defects in systemic cell-mediated immune responses
(183).
Cytokine Production in Infected Tissue
In approaching an analysis of the variables that contribute to
the expression of type I (severe) and type II (mild) lesions in
different inbred mice, it is crucial to identify the T cells and
cytokines that are present at the site of the lesions in vivo. The
assessment of cytokine gene expression in the lymph nodes of
mice infected with Mycobacterium leprae revealed that a Th1
pattern of response corresponded with the induction of pro-
tective immunity (348), and a similar approach has been used
to evaluate cytokine responses in the brains of CBA/CaH (type
I) and BALB/c (type II) mice after sublethal intravenous in-
fection with C. albicans.
These experiments failed to reveal any direct association
between Th1 and Th2 patterns of cytokine response and the
development of mild or severe lesions, in that cytokines typical
of both Th subsets were detected in these animals. mRNAs for
IFN-g, IL-6, and TNF-a were readily demonstrated in infected
mice of both strains but were present in significantly higher
concentrations in the mice with severe lesions (15). The fungal
burden and the severity of the tissue damage become estab-
lished before the increase in concentrations of the cytokine
mRNAs in the lesions, and yeast numbers peak at the same
time and fall at the same rate in both mouse strains. Although
the relative increase in the concentrations of IL-4 and IL-6 in
the brains of CBA/CaH mice, especially at day 5 after infection
(15), is consistent with a dominance of Th2 cells in the host
response, levels of the Th1 cytokine IFN-g were also consis-
tently higher in this strain. The current concept that domi-
nance of either the Th1 or Th2 subset determines whether a
particular mouse strain exhibits resistance or susceptibility to
C. albicans infection is clearly inadequate to explain these data.
An alternative hypothesis, for which there is some precedent
(246), is that infection is associated with successive waves of
CD41 cells, the first producing IFN-g and peaking at the time
at which protective immunity is fully expressed, and the second
secreting IL-4 and emerging at a time when the infection has
been contained.
In this particular model, there was also evidence in both
mouse strains of substantial activation or recruitment of CD81
cells. Screening of the brain cDNA for sequences coding for
CD4 and CD8 proteins showed that the concentrations of CD4
remained relatively constant in both strains, whereas there was
a 10-fold increase in CD8 mRNA levels in the brains of both
BALB/c and CBA/CaH mice between days 3 and 5 after in-
fection. CD81 lymphocytes with the ability to inhibit growth of
C. albicans hyphae in vitro (40) can be induced from mouse
lymph node (41) and spleen (42) cells by culture with rIL-2.
Furthermore, after culture with C. albicans and IL-2 in vitro,
CD81 lymphocytes kill Candida-infected neutrophils (290) and
express MHC-restricted cytotoxicity against Candida-infected
macrophage target cells (290, 291). CD81 lymphocytes secrete
IFN-g and other Th1 cytokines (130) but under certain circum-
stances can also produce Th2 cytokines such as IL-4 (67). In
fact, recent studies have shown that IL-12 and IL-4 promote
the development of type 1 and type 2 cytokine profiles, respec-
tively, in both CD41 and CD81 lymphocytes (85).
The role of CD81 T cells in the pathogenesis of infection
and resolution of tissue lesions in this model of systemic can-
didiasis remains to be explored. They may help to contain the
infection by lysing infected PMNL, releasing the microbicidal
agent calprotectin (218); they could contribute to recovery by
the production of cytokines that activate phagocytic cells; or,
alternatively, they may modulate the effector activity of CD41
Th cells, as has been demonstrated in Schistosoma mansoni
infection (80). Differences in the efficiency of lysis of infected
macrophages and PMNL by CD81 lymphocytes may also con-
tribute to the genetically determined dichotomy in the severity
of the lesions in different inbred strains of mice.
Discussion
It is pertinent here to recall the two themes central to the
analysis of host resistance to C. albicans infection. These are (i)
whether fundamentally different mechanisms are responsible
for the clearance of systemic as distinct from mucosal infec-
660 ASHMAN AND PAPADIMITRIOU MICROBIOL. REV.
tions and (ii) at what level does the immune (?) defect that
predisposes to recurrent mucosal infections occur.
Human studies have identified numerous effector pathways
that result in Candida killing, but to date, no convincing link
has been established between a particular clinical condition
and any specific effector mechanism. This statement does not
belittle the associations between systemic candidiasis and neu-
trophil deficiency or dysfunction and between chronic mucosal
infections and abnormalities in the cell-mediated immune re-
sponse; rather, it emphasizes that the effector mechanisms that
have been characterized are not unique to either condition. In
fact, cytokine-mediated augmentation of the phagocytic func-
tion of monocytes/macrophages and PMNL seems to provide a
unifying thread between the systemic immune response and
events occurring at the mucosal surface.
The recognition that cytokines represent not only a crucial
link between T lymphocytes and phagocytic cells but an im-
portant regulatory circuit for the T cells themselves (Fig. 2) has
led to a rapid expansion in our understanding of the mecha-
nisms that determine the outcome of experimental Candida
infections. A significant advance was the identification of the
reciprocal effects on susceptibility and resistance of cytokines
produced by the two subsets of CD41 Th lymphocytes. As
human lymphocytes also show a functional division into Th1
and Th2 subsets (281), this finding raised the possibility of
enhancing host resistance against systemic infection by redi-
rection of the cytokine response by using monoclonal antibod-
ies (220). Nevertheless, even though the Th1/Th2 paradigm has
provided a useful theoretical framework for the analysis of the
role of cytokines characteristic of these two T-cell subsets, it is
becoming apparent that there are data that cannot be accom-
modated by this deterministic approach.
One problem that may be unique to the Candida model is
the strain- and organ-dependent variability in the progression
and outcome of infection. At least three different variables
influence the host response to the yeast.
(i) Deficiency in C5. A deficiency in C5 would be expected to
influence the host response throughout the body, but in fact, its
effect is most clearly manifested in the kidney. Investigations of
the role of complement C5 in Candida infection have been
limited to its functions as an opsonin and chemoattractant, but
complement components, C5a in particular, can also initiate or
enhance the transcription and release of cytokines such as IL-1
and TNF (94) and thus exert a subtle influence on phagocytic
and immune interactions. There is considerable evidence that
differences in mortality in inbred strains are related to the
ability of the kidney to constrain growth of the yeast, and in this
specialized local environment, C5-mediated induction of cyto-
kines may act to augment the candidacidal or candidastatic
activities of resident phagocytes until these defenses are bol-
stered by recruitment of T lymphocytes and other inflamma-
tory cells from the blood.
(ii) Strain-dependent differences in tissue damage. The severity
of tissue damage in any particular inbred strain is under single-
gene control but is unrelated to the presence or absence of C5
and is independent of the extent or duration of Candida col-
onization. The question of whether this dichotomy reflects
differences in the intrinsic resistance of the tissue cells or in the
properties of cells of the hematopoietic system has been ad-
dressed by constructing radiation chimeras between type I and
type II mice. CBA/CaH mice, which exhibit severe lesions,
were lethally irradiated and reconstituted with MHC-compat-
ible bone marrow from BALB/k mice, which develop mild
lesions. When these animals were subsequently challenged
with a sublethal inoculum of C. albicans, lesions in the mice
that had received the BALB/k bone marrow were substantially
less severe than those in mice given syngeneic marrow (27).
This result provides clear evidence that genetic differences in
the extent of tissue damage in inbred mice are determined by
intrinsic properties of the bone marrow precursor cells; how-
ever, the effect cannot as yet be attributed specifically either to
the phagocytic cells or to the lymphocytes.
(iii) Organ-specific differences in fungal clearance. The total
burden of yeasts in any particular organ in a given inbred strain
may also determine the effectiveness of the host response in
clearing the organism from infected tissues. This effect is most
obvious in the brains of CBA/CaH and DBA/1 mice at 8 to 14
days after infection, but the mechanisms are at present un-
known.
All of these factors operate within different time frames, and
all add layers of complexity that need to be considered and
evaluated in the interpretation of experimental studies of host
responsiveness to C. albicans.
Comprehensive studies by Bistoni and his colleagues have
confirmed the importance of IFN-g in recovery from experi-
mental systemic infection and demonstrated that preferential
induction of IL-4 in certain mouse-yeast strain combinations
downregulates these protective responses. While there is no
doubt that these healer and nonhealer combinations display
the appropriate Th1 and Th2 cytokine profiles, a pivotal ques-
tion is how these become established in the host animals. This
question is particularly cogent in view of the fact that the
nature of the cytokine response can easily be modified by
changing the route of antigen presentation (systemic or muco-
cutaneous) and/or the Candida strain used (virulent or aviru-
lent), as well as by pretreatment with pharmacologically active
agents such as streptozotocin. A case in point is the response of
DBA/2 mice. In this strain, mortality is associated with the
development of a Th2 cytokine profile and survival is associ-
ated with a Th1 profile. However, the high mortality can be
attributed to the failure of the kidney to effectively constrain
proliferation and growth of the yeast, whereas in sublethally
infected mice, clearance and tissue damage in organs such as
the brain are not substantially different from those in the more
resistant strains. It follows that an improvement in survival in
this strain may be achieved by manipulations that enhance the
resistance of the kidney without necessarily affecting mecha-
FIG. 2. Cytokine responsiveness of T lymphocytes and NK cells. Only those
cytokines presently known to be relevant to C. albicans infection are shown.
LGL, large granular lymphocyte. Short arrows pointing inward indicate cytokines
that have an effect on the cell; those pointing outward indicate cytokines pro-
duced by the cell. The long arrows indicate regulatory pathways.
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nisms that determine clearance of the organisms from other
organs and tissues.
Recent studies with transgenic mice have shown that in the
absence of a strong phenotype-directing signal from the infec-
tious agent, the genetic background in any given inbred strain
can direct the development of the Th cells to a default pheno-
type (157), which in the DBA/2 strain is of the Th2 type. By
implication, when the mice are intravenously infected with a
sublethal dose, either recovery takes place despite the onset of
Th2 cytokine production, as has been demonstrated to occur
under certain conditions in murine cutaneous leishmaniasis
(308), or the reduced infectious load may allow the develop-
ment of a Th1 cytokine response. A precedent for qualitatively
different effects of quantitative changes in the antigenic stim-
ulus can be seen in the induction of tolerance or rejection after
challenge of female mice with large or small grafts of male skin
(8). A reduction in the magnitude of the fungal burden may
also account for the development of protective Th1-type im-
munity after mucosal infection (44), under which circum-
stances the infectious pressure on the systemic immune re-
sponse would be much reduced in comparison with infection
via the intravenous route. Alternatively, interaction of the
yeast with cells in the mucosa may lead to the local secretion of
IFN-g (122), which could direct the differentiation of periph-
eral CD41 T cells into the Th1 cytokine pathway.
The relationship between the immune response at the mu-
cosal surface or in a specific organ and that detected in the
systemic circulation is still obscure. In mucosal infections with
C. albicans, g/d T cells from all mouse strains may respond by
the production of Th1 cytokines, leading to the peripheral Th1
response reported for most mucosal models. On the other
hand, the type of Th cytokine profile elicited after systemic
infection may not necessarily reflect events occurring within
different organs or tissues, which may be influenced by site-
specific factors such as the relative susceptibility of the tissue or
the local fungal burden. Conversely, the extent to which the
systemic cell-mediated immune response can protect from or
ameliorate local or mucosal infections has yet to be clarified.
Although there is little doubt that central defects render pa-
tients susceptible to severe mucosal infections, active immuni-
zation of mice confers only limited additional resistance.
This is not altogether unexpected, as there is likely to be a
maximum rate at which the yeast can be eliminated from the
mucosa. The limiting factors at this site are probably the num-
ber and rate of recruitment of phagocytic cells rather than the
availability of T-cell-derived cytokines. As patients with chronic
mucosal infections do not display any obvious defects in phago-
cytic cell production or function, the immunological abnormal-
ities that lead to recurrent infection by the yeast are likely to lie
in the regulatory circuits that govern cytokine production.
IMMUNOREGULATION IN CANDIDA INFECTION
Immune Modulation in Human Disease
Active suppression of cell-mediated immune responses has
been associated with a number of fungal diseases (324), and
infection with C. albicans induces both specific and nonspecific
modulation of immune responsiveness. Polysaccharide anti-
gens of C. albicans generate a complex series of interactions
that result in the suppression of both T- and B-cell responses
to the homologous antigen (257). These effects are mediated
by an antigen-nonspecific inhibitory factor that is able to block
the synthesis of both IL-2 and IFN-g and the expression of the
Tac antigen (the IL-2 receptor) by normal human T cells (196).
This factor also inhibits antigen presentation and the produc-
tion of IL-1 by human monocytes (197). Another Candida
polysaccharide antigen has also been found to inhibit Candida-
specific proliferation of normal human lymphocytes (129). This
particular inhibitory activity—attributed to mannan—appears
to require both CD81 and CD82 suppressor cells and results
in the blockage of maturation of mannan-specific B cells (114).
Induction of the T suppressor cells requires HLA-DQ-compat-
ible macrophages; however, the interaction between T and B
cells is unrestricted.
Immunoregulation in Murine Candidiasis
Phenomena comparable to those in humans have been re-
ported for experimental animals. Systemic infection with C.
albicans induces a transient loss of lymphocyte proliferative
responsiveness to mitogens and to unrelated antigens (276). A
similar impairment of T-cell but not B-cell responses to mito-
gens was obtained after treatment of mice with formalin-killed
C. albicans (274). The effector cells, which were capable of
suppressing the T-cell-dependent proliferative response of nor-
mal cells, were identified as a surface immunoglobulin-positive
B lymphocytes. An antigen nonspecific suppressor population
of Lyb-2.11 B cells could also be elicited in vitro by culturing
normal splenocytes with formalin-killed C. albicans (88) and
with antigens derived from it (86). The B suppressor cells
required both T cells and accessory cells for their generation
(87) and inhibited both primary and secondary T-cell-depen-
dent antibody responses. However, they did not induce any
detectable changes in either T-cell effector function or T-cell-
independent antibody production (86). The same group has
shown that culture of splenocytes with an extract of Candida
cell walls generates a population of CD41 CD82 suppressor T
cells that inhibit primary and secondary antibody responses to
sheep erythrocytes (89).
Administration to mice of a Candida glycoprotein prior to a
standardized immunization regimen results in suppression of
DTH and lymphocyte proliferative responses to the homolo-
gous antigen and also diminishes the protective effects of im-
munization (71). C. albicans or its cell wall components can
also induce different immunomodulatory phenomena, such as
enhancement (91) or suppression (107) of antibody responses
to third-party antigens. The most potent immunomodulatory
activity has been associated with cell wall components of C.
albicans, in particular with the mannans and mannoproteins.
Mice injected with mannan at or near the time of immuniza-
tion displayed enhanced antibody responses to both a T-cell-
dependent (pneumococcal polysaccharide) and a T-cell-inde-
pendent (sheep erythrocyte) antigen (112). However, when
horse erythrocytes were used as a carrier for both the mannan
and the pneumococcal polysaccharide, either enhancement or
suppression of the antibody response was obtained. Although
the nature of the response in vivo depended on the amount of
mannan given with the immunizing antigen, the immunosup-
pressive and immunoenhancing components of the mannan
were separable by chromatography.
A preparation of mannan was more efficient than an extract
of cell wall glycoprotein in eliciting DTH responses from mice
infected with viable blastospores, but the converse was found
with lymphoproliferative responses (110). When mice were
treated with mannan intravenously prior to immunization
or, in the case of gastrointestinal colonization, between the
priming and secondary inoculations, DTH reactions to man-
nan were significantly and specifically suppressed (110). The
suppressor cells were characterized as Thy1 CD81 and, on
transfer to immunized recipient mice, suppressed DTH in a
dose-dependent manner (134). A similar inhibition of DTH
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responses was demonstrated by passive transfer of T suppres-
sor cells into cyclophosphamide-treated mice (336). The activ-
ity of the suppressor cells could be modulated so that they were
unable to exert a suppressive effect on DTH responses after
transfer into immunized mice if the donor mice were first
treated with monophosphoryl lipid A, an experimental thera-
peutic agent derived from lipopolysaccharide (111). Neverthe-
less, even though treatment of mice with mannan induced
profound inhibition of DTH responses, host resistance against
systemic infection in these mice was unaffected (135); in fact,
there was some evidence that mannan might actually have
enhanced protection.
In another study, a protein with a relative molecular mass of
43 kDa, isolated from culture supernatants of a virulent but not
an attenuated strain of C. albicans, was evaluated for its im-
munomodulatory effects in vivo (329). Treatment of mice with
this protein increased the number of immunoglobulin-secret-
ing plaque-forming cells in the spleen, specifically suppressed
the primary immune response against sheep erythrocytes, and
resulted in an increase in the number of yeasts in the kidney
after intraperitoneal challenge. The immunosuppressive and
B-cell mitogenic properties were directly correlated and showed
an inverse relationship with the ability to induce susceptibility to
C. albicans infection. Immunization of BALB/c mice with the
protein partially neutralized the immunomodulatory effects (328)
and fully protected the mice against the fungal infection.
Given that there is cogent evidence for a variety of immu-
nomodulatory events associated with C. albicans infection, the
point at issue is not the immunosuppressive potential of the
yeast per se, but whether there exists a particular type of
immune modulation that occurs within a genetically defined
host environment and is associated with a differential suscep-
tibility to infection.
Genetic regulation of immune responses. At present, the
only documented differences in T-cell responses to primary C.
albicans infection in type I and type II mouse strains are lower
numbers of inflammatory cells but a higher proportion of T
cells in the draining lymph node of a susceptible strain (CBA/
CaH) after subcutaneous injection (9, 21). However, the evo-
lution of the immune response, as reflected in assays of mem-
ory T-cell function, appears to be subject to different forms of
regulation in type I and type II mice (Table 6). Both DTH and
Candida-specific lymphoproliferative responses are signifi-
cantly weaker in CBA/CaH than in BALB/c mice; however, in
BALB/k mice, which have the same MHC haplotype as CBA/
CaH mice, the magnitude of the memory responses is not
significantly different from that in BALB/c mice (11). This
differential responsiveness is governed not by MHC genes, as
in the primary response, but by background or non-MHC
genes. The weak T-cell memory responses in CBA/CaH mice
are also associated with the occurrence in high frequency in
this strain of a chronic osteomyelitis in the vicinity of the inner
ear (25) that persists for at least 6 months.
A further analysis of the reactivity of activated spleen cells
from CBA/CaH and BALB/c mice revealed a dichotomy be-
tween the presence of IFN-g mRNA and protein production
(14). mRNA for IFN-g was demonstrated in primary and sec-
ondary cultures of both BALB/c and CBA/CaH lymphocytes as
well as in immune cells cultured in the absence of Candida
antigen, but biological assays revealed that on days 3 and 5 of
culture, functional IFN-g protein was secreted by lymphocytes
from BALB/c but not CBA/CaH mice. Although the cell pop-
ulations used in these experiments were heterogeneous and
the readouts may have included extraneous responses, such as
to fetal calf serum, the important point is that there is a func-
tional difference between the reactivity of lymphocytes from
BALB/c and CBA/CaH mice after culture in vitro with Can-
dida antigens. Similar results were obtained independently by
Romani et al. (288), who showed that even though IFN-g
mRNA was present in CD41 and CD81 lymphocytes from
mice with either self-limiting or progressive infections, IFN-g
protein was produced only by lymphocytes from mice with
self-limiting infections.
These data are consistent with the existence of qualitatively
different regulatory mechanisms in strains of mice showing
different patterns of tissue damage, and immunological cross-
reactivity resulting in the generation of autoimmune responses
has been proposed as a mechanism to explain both the gener-
alized and specific unresponsiveness induced as a consequence
of C. albicans infection (86) and the increased susceptibility to
infection of patients with recurrent Candida vaginitis (20).
MOLECULAR MIMICRY
The concept of molecular mimicry in C. albicans infection is
not new. Antibodies to single-stranded DNA were detected
and found to correlate with disease activity in patients with
chronic mucocutaneous candidiasis (366), and of more rele-
vance to this discussion, patients with chronic vaginal candi-
diasis displayed high titers of antiovarian and antithymocyte
antibodies (210). Significantly, the T-lymphocyte-specific anti-
bodies in these patients were directed primarily against helper
T cells. C. albicans also expresses cell surface receptors for the
C3 fragment iC3b (141), which cross-react with some but not
all monoclonal antibodies against epitopes of the human C3
receptor (216). However, although the fungal and human C3
receptors cross-react and bind identical ligands, they have been
found to differ in structure (2). Other serological cross-reac-
tivities have been demonstrated. A protein of C. albicans re-
acted with a monoclonal antibody (MY9) specific for a mono-
cyte antigen (216), and yeast-phase cells express a protein that
is antigenically and structurally related to CD11b/CD18, a
member of the b2 family of integrins (145).
Heat shock protein 90 (hsp90) is an important regulatory
protein in humans, and an antibody to a 47-kDa breakdown
product of hsp90 is found in high frequency in the serum of
patients recovering from disseminated candidiasis (215) and in
the serum of patients with AIDS (213). These observations led
to the suggestion that it may have a protective function, and
further studies showed that an autoantibody to hsp90 could
protect mice against systemic infection (214). This group has
pointed out the apparent paradox that the recognition of self-
reactive epitopes of heat shock proteins in Candida and other
infections does not lead to autoimmune disorders (212) and
suggested that such reactivity might take place within an ‘‘im-
munological homunculus’’ (82) consisting of preformed regu-
latory networks that channel the response into regulated path-
TABLE 6. Summary of immunological reactivity in inbred and
congenic resistant mice after primary and secondary
challenges with C. albicans
Strain MHCtype
Lesion
type
Primary
responsea
Secondary
responseb
CBA/CaH H-2k Severe Low Low
BALB/c H-2d Mild High High
BALB/k H-2k Mild Low High
aMeasured as the increase in cell numbers in the popliteal lymph nodes after
infection via the footpad (9).
b Represents the magnitude of DTH and lymphocyte proliferative responses in
mice that had recovered from a primary infection with C. albicans (11).
VOL. 59, 1995 CYTOKINES IN IMMUNITY TO C. ALBICANS 663
ways, preventing the development of autoimmune diseases.
Nevertheless, genetic and other factors might conspire in some
individuals to defeat the regulatory response, leading to auto-
immunity.
In this context, the immune system has been shown to main-
tain a screening process in the periphery that can detect and
induce tolerance in potentially autoreactive cytotoxic T lym-
phocytes (144). The process depends on the presence or ab-
sence of Th cells, in that if T help is available, the cytotoxic
precursors are activated, whereas in the absence of help, the
cells become tolerant. However, tolerance of CD41 cells ap-
parently does not result in clonal deletion, as infection with the
nematode Nippostrongylus brasiliensis is able to break T-cell
tolerance established by injection of mice with Staphylococcus
enterotoxin B (275), resulting in the clonal expansion in vivo of
the Vb81 CD41 cells. The persistence of potentially autore-
active T cells in the periphery was demonstrated many years
ago by Blanden et al. (50), who also postulated that T-cell
tolerance might be a quantitative phenomenon, related to the
density of self-antigens to which the T cells were exposed
during differentiation and selection in the thymus (49). A sim-
ilar hypothesis has been invoked to explain the antigen-specific
reactivity of self-tolerant unresponsive T cells (178). A neces-
sary corollary is that an increase in the density of self-antigens
should lead to the breaking of self-tolerance. This could be
caused by, for example, cross-reactive antigens present on in-
fectious agents or upregulated by infection.
Two different lines of evidence are relevant to Candida in-
fection. First, human oral mucosa affected by C. albicans (170)
and the lesions of angular cheilitis infected with C. albicans
(245) displayed increased expression of HLA-DR by epithelial
cells and keratinocytes, respectively. In both cases, an intense
intraepithelial infiltration of T lymphocytes was observed, sug-
gesting that the increased expression of the MHC class II
antigens might be induced by T-cell-associated cytokines. Sim-
ilar findings were obtained in mice (13) except that, in these
experiments, a culture supernatant of C. albicans was effective
in directly enhancing expression of MHC class II antigens in
both LK cells (an antigen-presenting murine cell line) and
thioglycolate-induced mouse macrophages. Thus, there is a
quantitative increase in the expression of self-antigens during
Candida infection, a prerequisite for breaking self-tolerance,
as predicted by the theory.
Second, an analysis of the reactivity of activated spleen lym-
phocytes from CBA/CaH and BALB/c mice that had recovered
from a primary systemic infection with C. albicans revealed
that cells frommice of the former strain are capable of expressing
autoreactivity, as measured by an increase in footpad thickness,
after injection into the footpad of syngeneic normal mice in the
absence of any further exposure to Candida antigens (12). This
reactivity is mediated by CD42 CD81 T cells and is directed
against antigens expressed in (BALB/c3 CBA/CaH)F1 but not
in (BALB/c 3 BALB/k)F1 hybrid mice. The activated cells did
not display either specific nor nonspecific cytotoxicity, but as
limiting-dilution analysis was not attempted, the existence of a
minor population of cytotoxic cells could not be formally ex-
cluded. These data have been interpreted as favoring the ex-
istence in CBA/CaH but not in BALB/c mice of some form of
immunoregulatory mechanism that has been activated as a
consequence of molecular mimicry between Candida antigens
and those of the host (24).
When viewed in this perspective, the various lines of evi-
dence are consistent with the hypothesis that self-tolerance in
type I mice is broken by infection. Regulatory mechanisms may
then come into play to control the aberrant responses, so that
the end result is not autoimmunity but the weakening of host
defense mechanisms against the yeast. It is tempting to spec-
ulate that the weak DTH responses in these mice reflect the
suppression of CD41 helper cells and that the effector cells
suppressed by the response are CD81 cytotoxic cells specific
for a determinant common to both yeast and host.
CONCLUSION
The general picture that is emerging from the mouse studies
indicates that interactions at many different levels determine
the outcome of mucosal or systemic challenge (Fig. 3). A
striking feature of the relationship between C. albicans and the
host is the subtle way in which responses vary under different
conditions of systemic infection, especially as there is a narrow
window for the establishment of disease before mortality su-
pervenes. For reasons that are still unclear, some physiological
quality of the mouse kidney determines the threshold at which
animals will die, and stimulation of macrophage activation by
nonspecific agents or through the Th1-mediated cytokine path-
way enhances the resistance of this organ and increases sur-
vival. When the infectious challenge is reduced to a sublethal
dose, differences in the innate resistance of inbred strains be-
come more obvious.
Altering the route via which Candida antigens are presented
to the immune system, such as infection via the gastrointestinal
tract rather than intravenously, can change the outcome of
challenge from early mortality to systemic immunity and pro-
tection against reinfection. This effect could be mediated by
qualitative differences in antigen processing or presentation or
FIG. 3. Schematic illustrating alternative pathways in the host response to
systemic and mucosal infection with C. albicans.
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by a direct effect of the antigenic load, but the pathways via
which these effects are mediated remain to be defined. Clearly,
these differences could be actively reinforced by the immuno-
modulating properties of mannan and other mannoprotein
constituents of the yeast. These moieties may also interact with
established immunoregulatory pathways that maintain self-tol-
erance to attenuate the specific response against the yeast in
certain genetically susceptible hosts.
Although substantial progress has been made in the analysis
of mechanisms of recovery from systemic candidiasis, the re-
lationship between systemic and mucosal responses and the
nature of the defect that leads to chronic disease remain major
challenges for future research.
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